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I. Abstract 
 
The c-myc gene encodes for a transcription factor involved in the regulation of different 
cellular mechanisms, ranging from cell cycle control and apoptosis to cellular metabolism. 
Myc is frequently altered in human cancer either by genomic rearrangement or by 
alteration of upstream regulatory pathways. Myc crucial role both in tumor formation and 
maintenance makes it an attractive molecular target for cancer therapy. Unfortunately, 
Myc is intrinsically resilient to direct pharmacological targeting using small molecules. 
To overcome this issue, alternative therapeutic avenues have been explored. In the last 
years, independent groups showed that BET proteins inhibition leads to a strong Myc 
downregulation in Multiple Myelomas and Acute Myeloid Leukemias, with consequent 
cell cycle arrest and tumor regression. To support the hypothesis of a direct and specific 
effect on Myc levels mediated by BET proteins, two different working models were 
proposed depending on c-myc location (translocated versus endogenous).  
In order to extend these observations and improve our understanding of the mechanism of 
action of BETs inhibitors, we evaluated global transcriptional alteration and chromatin 
profiles in Burkitt’s Lymphomas in response to JQ1.  
Our results demonstrate that BETs inhibitors efficacy is dependent on global alteration of 
RNA PolII dynamics, due to the role of BRD4 in regulating elongation. Yet, despite a 
pervasive eviction of BRD4 from chromatin and the global effect on RNA PolII observed 
following BETs inhibition, the transcriptional alterations are limited to a subset of genes. 
These genes are characterized by promoter regions heavily marked by H3K27Ac, high 
binding of BRD4 and Transcription Factors (Myc and E2F1) and RNA PolII. These JQ1 
sensitive genes are consistent among different cell lines and characterized by high 
expression levels.  
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Prominent promoter saturation and high RNA PolII pausing render their expression rate-
limited by transcriptional elongation. Indeed the same genes are selectively targeted by 
pharmacological treatments affecting components of the elongation machinery. Thus, 
selective transcriptional effects following JQ1 treatment are linked to BETs role in 
regulating transcriptional elongation. These observations highlight the role of BETs 
protein in regulating gene expression and provide a rationale to explain how broad 
inhibition of elongation may lead to a selective transcriptional response. 
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II. Introduction 
 
MYC 
 
The myc gene was first identified as the avian retroviral oncogene v-myc responsible of the 
transforming capacity of the MC29 avian virus  (Sheiness and Bishop, 1979), only later its 
cellular counterpart was identified  (Vennstrom et al., 1982). c-myc is a member of a larger 
family comprising also L-Myc and N-Myc. All the family members share high structural 
homology and exert their transcriptional function by binding to the cofactor Max  
(Blackwood and Eisenman, 1991). The c-Myc protein is characterized by different N-
terminal Myc homology Boxes (MB), which are also conserved in the other family 
members. In particular, the most relevant for Myc function are MBI and MBII, that 
respectively contain key phosphorylation sites (Thr58 and Ser62) and binding domains for 
co-activators as TRRAP. The Myc protein contains also a Transactivator Domain (TAD), 
needed for the activation of transcription, and a Nuclear Localization Signal (NLS), 
necessary for the proper subcellular localization. The helix-loop-helix-leucine-zipper 
domain (HLH-LZ) and the basic region (BR) are located at the C-terminus and are 
necessary for the dimerization with Max and for the binding to specific DNA sequences, 
respectively. 
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Fig. 1 Myc protein structure 
Schematic representation of the Myc protein structure where an N-terminal Domain (NTD), a central region 
and a C-terminal Domain (CTD) are highlighted. The NTD contains the Trans-Activator Domain (TAD), 
necessary for gene activation, and the Myc homology Boxes (MB). In particular MBI and MBII are 
depicted: MBI contains key phospho-sites (Thr58 and Ser62), while MBII contains protein-protein 
interaction domain. In the central region is located the Nuclear Localization Signal (NLS). Finally, the CTD 
contains the Helix-Loop-Helix-Leucine-Zipper (HLH-LZ) domain, necessary for the dimerization with Max, 
and the Basic region (b) needed for the binding to the DNA.  
Figure adapted from “c-myc: more than just a matter of life and death.”  (Pelengaris et al., 2002)  © 2015 
Macmillan Publishers Limited. All Rights Reserved. 
 
Transcriptional and post-translational regulation of Myc 
Since Myc is involved in different cellular processes and its deregulation is associated to 
tumor formation, Myc expression is tightly regulated at different levels, ranging from the 
transcriptional control to protein degradation.  
The c-myc gene is characterized by the presence of at least 4 different promoters (P0, P1, 
P2 and P3) located before the second exon, which contains the starting codon. The most 
used promoter is P2 that, together with P1, contains both TATA boxes and Initiator (Inr) 
sequences. P0 and P3 are less used and they are TATA-less promoters  (Wierstra and 
Alves, 2008).  
 
Fig. 2 The c-myc gene structure 
The c-myc gene is composed by 3 exons, with the starting codon located in the second exon. At least 4 
different promoters, located upstream of the second exon, were identified so far.  
Figure adapted from “The c-myc Promoter: Still MysterY and Challenge” (Wierstra and Alves, 2008)  
Copyright © 2007 Elsevier Inc. All rights reserved. 
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In Myc promoter a plethora of binding sites for different TFs were identified  (Wierstra 
and Alves, 2008). Evidences were provided for the positive regulation of c-myc 
transcription mediated by WNT  (He et al., 1998; Sansom et al., 2007), JAK/STAT  
(Bromberg et al., 1999; Kiuchi et al., 1999), Notch  (Palomero et al., 2006; Sharma et al., 
2006; Weng et al., 2006) and Hedgehog  (Berman et al., 2002; Sicklick et al., 2006), while 
TGFβ represses c-myc transcription  (Chen et al., 2002; Frederick et al., 2004).  
 
Fig. 3 Transcriptional regulation of the c-myc gene 
c-myc transcription is regulated by a plethora of different signaling pathways. Among the most relevant, 
activating signals are mediated by Hedgehog, WNT, Notch, JAK-STAT pathways, while negative regulation 
is exerted by TGFβ signaling.  
Figure adapted from “MYC: connecting selective transcriptional control to global RNA production” (Kress 
et al., 2015)  © 2015 Macmillan Publishers Limited. All Rights Reserved. 
 
Myc is one of the first genes for which the regulation of the elongation step and the 
presence of RNA PolII paused at the promoter were observed. Indeed, Myc is not 
expressed in quiescent cells but its transcription is immediately activated in response to 
mitogenic stimuli. This immediate response is favored by the presence of promoter-
proximal paused RNA PolII, ready to be released as soon as the stimulus is triggered  
(Bentley and Groudine, 1986; Nepveu and Marcu, 1986). Once Myc is transcribed, it 
could be regulated both at the post-transcriptional and post-translational levels. Indeed 
both, Myc mRNA and protein have a very short half life (20-30 minutes) due to active 
mechanisms that shorten the mRNA or destabilize the protein through phosphorylation of 
key residues. In particular, mitogenic stimuli induce the phosphorylation on Ser62, 
necessary for the stabilization and activation of Myc protein. At the same time, phospho-
Ser62 serves as a scaffold for the recruitment of GSK3β that in turn phosphorylates Thr58, 
thus causing the subsequent ubiquitination and degradation of the Myc protein  (Meyer 
and Penn, 2008; Vervoorts et al., 2006). 
  Introduction 
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Fig. 4 Schematic representation of Myc protein degradation 
Two critical residues are responsible of Myc protein degradation: Thr58 and Ser62. Ser62 is phosphorylated 
in response to mitogenic stimuli and, while enhancing Myc activity, creates a scaffold for the binding of 
GSK3β that leads to the phosphorylation of Thr58. After this second phosphorylation event, the 
oncosuppressor FBW7 is bound and it recruits SCF, favoring Myc ubiquitination and proteosomal 
degradation.  
Figure adapted from “The Ins and Outs of MYC Regulation by Posttranslational Mechanisms”  (Vervoorts et 
al., 2006) © 2006 by The American Society for Biochemistry and Molecular Biology, Inc. 
 
Besides the direct regulation of Myc mRNA and protein, another layer of control is 
represented by the availability of Max. Indeed, Myc recognition of the DNA target 
sequences is mediated by the dimerization with its partner Max  (Amati et al., 1992). 
Differently from Myc, Max is constitutively expressed and it could dimerize also with 
other HLH-LZ proteins as Mad, a Myc antagonist that, recognizing Myc target sequences, 
represses genes that are usually activated by Myc. Thus, the amount of free Max and the 
balance of Myc-Max and Mad-Max dimers represent an additional step in the control of 
Myc activity  (Grandori et al., 2000). 
 
Myc as transcription activator 
The Myc-Max heterodimer shows a preference for specific DNA sequences, called E 
boxes (CACGTG). Its binding to chromatin allows the recruitment of different co-
activators and chromatin remodeling factors such as pTEFb  (Rahl et al., 2010) TRRAP  
(McMahon et al., 1998) CBP and p300  (Vervoorts et al., 2003), as well as RNA PolII 
itself  (Koch et al., 2007). Indeed, the function of Myc as transcription activator could be 
simplistically summarized as a first step of recruitment of chromatin modifiers, favoring 
the deposition of marks of transcriptional activation, and a second step of enhancement of 
elongation, favoring the release of promoter paused RNA PolII. Different evidences 
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showed that Myc, via its MBII domain, could directly bind TRRAP  (McMahon et al., 
1998) and recruits on the promoter Histone Acetyl Transferases (HATs)  (McMahon et al., 
2000). Finally, after inducing chromatin acetylation at promoters, Myc could recruit RNA 
PolII and pTEFb to enhance the release of the stalled RNA PolII and induce the 
transcriptional elongation  (Eberhardy and Farnham, 2002; Rahl et al., 2010). Myc is not a 
pioneer factor, meaning that it is not able to bind closed chromatin and cannot recognize 
target sequences when they are buried into the nucleosome structure. Indeed, it was 
demonstrated in reprogramming experiments that, while Oct4, Sox2, Klf4 (OSK) were 
able to act as pioneer factors by binding closed chromatin and unwinding the DNA, Myc 
only bound the DNA subsequently to OSK  (Soufi et al., 2012).  
Moreover, Myc binding to its target sequences required the presence of specific chromatin 
modifications characteristic of active regulatory regions as H3K4me1, H3K4me2, 
H3K4me3, H3K27Ac. Furthermore, DNA sequences bound by Myc are usually located in 
regions enriched for CpG islands  (Sabò et al., 2014).  
Different mechanisms have been proposed for Myc recognition and binding to its target 
sequences: one above all better summarizes what is known so far on Myc and predicts that 
target recognition occurs as a multistep process with a first phase of protein-protein 
interaction with the already assembled basal transcription machinery (Pre-Initiation 
Complex (PIC)) and with the chromatin “readers” that decipher the histone modifications. 
Once these regions are identified, the Myc-Max heterodimer makes contact with DNA and 
scans the open chromatin stretch in order to find high affinity regions to bind. The 
recognition of the E-boxes allows the transition from a low-affinity to a high-affinity 
binding among Myc-Max and the DNA, this interaction is further stabilized by the 
protein-protein contacts with the basal transcription machinery  (Sabò and Amati, 2014).  
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Fig. 5 Schematic model for Myc-Max dimer DNA recognition 
The recognition of Myc target sequences, the E-boxes (CACGTG), follows the formation of Myc-Max 
dimer. Initially, Myc-Max dimer takes contacts with the basal transcription machinery (Pre-Initiation 
Complex (PIC)) and with chromatin readers. Subsequently, the dimer binds with low affinity and scans the 
DNA stretch, until the E-box is found and bound with high affinity.  
Figure adapted from “Genome Recognition by Myc” (Sabò and Amati, 2014) Copyright © 2014 Cold Spring 
Harbor Laboratory Press; all rights reserved. 
 
The intensity and the number of sites bound by Myc change strongly based on the cell line 
analyzed and depend on the endogenous Myc levels  (Sabò and Amati, 2014). There is 
ample evidence showing that, when expressed at physiological levels, Myc binds only 
canonical E-boxes, preferentially at the promoter, with relative high affinity. In cells 
where Myc is deregulated and overexpressed, its binding is no longer restricted to specific 
DNA sequences, but can also occurs on not-canonical E-boxes present in distal regulatory 
regions. In this scenario, virtually all the regulatory regions are bound by Myc causing a 
phenomenon called “invasion”  (Sabò et al., 2014). 
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Myc regulates transcriptional elongation 
Myc can regulate the expression of its target genes either by activating or repressing them 
after the binding to regulatory regions usually located on the promoter. The promoter is 
defined as a DNA region surrounding the Transcription Start Site (TSS) and that is 
essential both for the assembly of the Pre-Initiation Complex (PIC) and for the recruitment 
of specific Transcription Factors (TFs) that ensure the fine regulation of the expression of 
the target genes. Similar to promoters for DNA composition and modular assembly of TFs 
binding sites, the enhancers can regulate the transcription of associated genes in an 
orientation- and distance-independent manner.  
TFs and co-activators recruited to promoter associated regulatory regions can control gene 
expression by affecting different steps of the transcription process: initiation, elongation 
and termination. During the initiation step, RNA PolII and General Transcription Factors 
are recruited on the promoter. While first studies on gene transcription claimed that the 
recruitment of RNA PolII represented the limiting step in the regulation of gene 
expression, recent evidences demonstrated that RNA PolII, once on the TSS, is not 
immediately engaged in the transcription process, but instead it is retained on the promoter 
in a stalled condition  (Krumm et al., 1992; Plet et al., 1995; Rasmussen and Lis, 1993; 
Rougvie and Lis, 1988; Strobl and Eick, 1992). Indeed, different modifications are 
required to prime RNA PolII and enhance its processivity, among which the most 
characterized are the phosphorylation on Serine 5 (Ser5) and Serine 2 (Ser2) of the 
Carboxy-Terminal Domain (CTD). The phospho-residue on Ser5 is needed for RNA PolII 
priming and it is added by CDK7, a component of the TFIIH in the PIC complex  
(Sainsbury et al., 2015). Instead, the Ser2 is phosphorylated by CDK9 that, together with 
Cyclin T1, is part of the positive Elongation Factor (pTEFb). The phosphorylation on Ser2 
is necessary for promoter clearance and the progression of transcription through the 
elongation step. pTEFb further pushes the RNA PolII toward the elongating form 
phosphorylating negative transcription regulators as NELF and DSIF, that in physiological 
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condition block RNA PolII in a promoter-proximal paused state  (Buratowski, 2009; 
Jonkers and Lis, 2015). Finally, the transcription process ends as soon as RNA PolII 
encounters the Transcription End Sites (TES), that contain the information for its release 
from chromatin  (Porrua and Libri, 2015).  
Recent evidences show that Myc can actively enhance the elongation step by directly 
recruiting pTEFb on the promoter of its targets  (Rahl et al., 2010). Accordingly, Myc-
Max inhibition caused a strong reduction in the elongating and Ser2 phosphorylated RNA 
PolII, while no changes were observed on RNA PolII recruited on the promoter or on the 
amount of polymerase phosphorylated on Ser5  (Rahl et al., 2010).  
 
Myc role in cell cycle progression and apoptosis 
Myc regulates transcriptional programs involved in different aspects of cell life, ranging 
from the cell cycle control to regulation of cell growth, apoptosis, cell metabolism and 
ribosome biogenesis  (Ponzielli et al., 2005).  
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Fig. 6 Myc regulatory network 
Myc is a key transcription factor involved in the regulation of different biological process, ranging from cell 
cycle progression and apoptosis to angiogenesis and cellular differentiation.  
Figure adapted from “Cancer therapeutics; Targeting the dark side of Myc”  (Ponzielli et al., 2005) ©2005 
Elsevier Ltd. All rights reserved.  
 
Since Myc is a transcription factor, it exerts its function through the regulation of key 
genes involved in different processes. Indeed, the positive effect exerted by Myc in the 
control of the cell cycle can be explained by the transcriptional activation mediated by 
Myc of genes essential for the cell cycle progression, such as Cyclin D1, D2, E1, 
CDC25A, E2F1, E2F2, CDK4  (Meyer and Penn, 2008; Obaya et al., 1999; Oster et al., 
2002). Beside the transcription activator function, Myc can act as a transcriptional 
repressor, inhibiting the expression of specific genes. This is particularly relevant for cell 
cycle progression, where Myc importance is not only limited to the activation of the genes 
mentioned above, but it is critical also for the repression of cell cycle check point genes 
(GADD45 and GADD153) or for the inhibition of CDK inhibitors  (Meyer and Penn, 
2008). Myc is also involved in the regulation of apoptosis by acting on the ARF-MDM2-
p53 axis, both activating ARF and concomitantly inhibiting p21. This aspect of Myc 
biology is particularly relevant in tumor onset: indeed, different publications clearly 
demonstrated that oncogenic Myc and concomitant inactivation of p53 or increased 
expression of anti-apoptotic factors as BCL2 led to an acceleration of tumor onset  (Meyer 
and Penn, 2008; Strasser et al., 1990). 
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Myc in cancer 
Given its crucial role in different aspects of cell life and in particular in the control of cell 
cycle and cell growth, Myc deregulation is associated to different types of cancer. Indeed, 
Myc expression is altered in a wide spectrum of tumors, ranging from hematological to 
solid tumors. The most common alteration of Myc expression involves gene translocation 
and amplification, while point mutations are more rare and usually lead to an increase in 
protein stability. In particular, Myc amplification is more frequent in solid tumors, indeed 
it is found in ~30% of Hepatocellular carcinoma, in 9-45% of Breast cancers and in 40% 
of Ovarian cancers; while Myc translocation is commonly associated to hematological 
disorders, in fact it is present in 100% of Burkitt’s Lymphomas (BL) and ~15% of 
Multiple Myeloma (MM), where c-myc is translocated under the control of the 
Immunoglobulin regulatory regions  (Vita and Henriksson, 2006). The translocation 
responsible of the onset of BL involves chromosome 8, in which c-myc is located, and 
chromosome 14, 2 or 22 where the regulatory regions for the immunoglobulin heavy and 
light chains are located  (Molyneux et al., 2012). 
 
Fig. 7 Schematic representation of the c-myc gene rearrangement  
Myc deregulation in cancer could be achieved by different mechanisms as gene amplification, typical of 
solid tumors, or genomic rearrangement, typical of hematopoietic malignancies. In particular 100% of BL 
and ~15% of MM are characterized by chromosomal translocation that juxtaposes the c-myc locus to the 
Immunoglobulin regulatory regions of the heavy, or more rarely of the light, chain.  
Figure adapted from “Reflecting on 25 years with Myc”  (Meyer and Penn, 2008) © 2008 Macmillan 
Publishers Limited. All Rights Reserved. 
 
Beside these gross genomic alterations, Myc expression can be deregulated also by the 
impairment of upstream pathways. One example is provided by Acute Myeloid Leukemia 
(AML) where the fusion oncoprotein MLL-AF4/9 directly activates c-myc transcription. 
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Furthermore, key Myc aminoacids could be mutated in cancer: one hotspot is represented 
by the residue Thr58 that when phosphorylated leads to Myc degradation via proteasome. 
Mutations on this residue not only ensure a longer protein half life, but also confer 
oncogenic properties separating the regulation of the cell cycle progression from the 
control of the apoptosis mediated by Myc. Indeed, mutant Myc on Thr58 is unable to 
induce BIM expression that inhibits BCL2, with the final result of the bypass of the 
apoptotic response and an acceleration of lymphomagenesis  (Hemann et al., 2005).  
 
Myc as a therapeutic target 
As mentioned above, Myc is often associated to cancer since it is necessary both for tumor 
formation and tumor maintenance. The central role exerted by Myc in tumor maintenance 
was highlighted in experiments using conditional mice in which Myc expression could be 
modulated in a reversible way. In particular, if Myc expression was switched off in 
established tumors, tumor shrinkage and regression were observed, both in hepatocellular 
carcinoma  (Shachaf et al., 2004) and in pancreatic cancer  (Pelengaris et al., 2002a). It is 
worth to note that the response to Myc downregulation is tumor-type specific, since 
lymphomas undergo apoptosis, osteosarcoma cells are forced to differentiate while 
hepatocellular carcinomas show an heterogeneous response, indeed the vast majority of 
carcinoma cells die for apoptosis and few cells remain dormant and ready to re-establish a 
new tumor once Myc expression is restored  (Gabay et al., 2014). The crucial role of Myc 
in tumor maintenance was demonstrated also in tumors driven by other oncogenes, as in 
Kras driven lung cancers  (Soucek et al., 2008). Indeed, modulating the expression of a 
Myc dominant negative (Omomyc) (Soucek et al., 1998), and therefore blocking Myc 
transcriptional activity, was sufficient to cause strong regression also in already 
established Kras tumor. Since Myc is essential for the regulation of normal cell 
proliferation, this study assessed also the side effects of a systemic Myc inhibition. Indeed, 
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a prolonged Omomyc induction led to defects in spermatogenesis, hair production and 
epidermal thickness. However, these effects were well tolerated and reversible, since the 
animals did not show any weight loss and, after Myc restoration, the proliferation in the 
normal tissues was reinstated  (Soucek et al., 2008). 
Due to its involvement both in tumor formation and maintenance and since its 
downregulation is clearly associated to tumor regression and cellular differentiation, the 
possibility to target Myc represents a tempting therapeutic option. Unfortunately, Myc, as 
other transcription factor, does not possess a ternary structure suitable for direct drug 
targeting. Thus, different approaches have been used in order to overcome this obstacle: 
the main strategies evaluated so far range from inhibition of c-myc expression, using 
AntiSense Oligonucleotides (ASOs), to transcription inhibition thanks to the use of Triple 
helix Forming Oligonucleotides (TFOs) or porphyrins that create a physical obstacle for 
RNA PolII. Another promising alternative is represented by the possibility to prevent the 
dimerization with Max, through the use of Myc dominant negative, as Omomyc  (Soucek 
et al., 1998, 2002). Each of these approaches shows limitations in particular for clinical 
applications, concerning molecules stability, half-life and feasibility to reach the right 
target  (Ponzielli et al., 2005).  
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BET proteins 
 
BET family 
Chromatin is a target of several Post-Translation Modifications (PTMs), ranging from 
acetylation to ubiquitination, which are produced by a class of proteins collectively called 
“writers”. These modifications are thought to provide a “code”, which contains epigenetic 
information. This code is deciphered by proteins called “readers” which are able to 
recognize specific PTMs, and eventually reset by “erasers”, proteins capable of removing 
PMTs.  (Filippakopoulos and Knapp, 2014).  
 
Fig. 8 Histone modifications and proteins involved in histone modification 
Histone proteins usually are subjected to post translation modification mediated by “writers” that are 
devoted to add phospho, methyl, acetyl or other groups. This code is read by a specific class of proteins 
called “readers” and eventually removed by “erasers”. Histone Acetyl Transferares, Kinases and Histone 
Methyl Transferases are members of the writer class; among the readers are included bromodomain and 
chromodomain, while Histone Deacetylases, Phosphatases and Demethylases composed the eraser class.  
Figure adapted from “Targeting bromodomains: epigenetic readers of lysine acetylation”  (Filippakopoulos 
and Knapp, 2014) © 2014 Macmillan Publishers Limited. All Rights Reserved. 
 
In particular, the acetyl group is added to lysines by the Histone Acetyl Transferases 
(HATs) and is detected by bromodomain containing proteins, such as those belonging to 
the BET family (Bromodomain and Extra-Terminal containing proteins). The BET family 
is composed of 4 different nuclear proteins (BRD2, BRD3, BRD4 and BRDT) 
characterized by two tandem bromodomains (BD) and an Extra-terminal (ET) domain.  
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Fig. 9 Schematic representation of BETs proteins 
The BET family is composed of 4 different members: BRD2, BRD3, BRD4 and BRDT. All the members are 
characterized by 2 N-terminal bromodomains (BD) and one Extra-Terminal domain (ET). While for BRD2, 
BRD3 and BRDT only one isoform is known, for BRD4 3 different isoforms exist.  
Figure from “The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition”  (Shi and 
Vakoc, 2014)  ©2014 Elsevier Inc. 
 
The bromodomain was first identified in the Drosophila brahma gene and is composed by 
4 α-helices and 2 loops that create a hydrophobic pocket where the acetylated lysines are 
bound. In the human genome 61 bromodomains have been identified, distributed in 46 
different proteins that cluster in 8 different families. 
 
Fig. 10 Phylogenetic for bromodomain proteins 
In humans the bromodomain containing proteins are divided in 8 different classes, based on protein 
structure. In total, 61 different bromodomains organized in 46 different proteins were indentified. 
Figure adapted from “Targeting bromodomains: epigenetic readers of lysine acetylation”  (Filippakopoulos 
and Knapp, 2014) © 2014 Macmillan Publishers Limited. All Rights Reserved. 
 
Thanks to its peculiar 3D structure, the bromodomain pocket is amenable to small 
molecule targeting. Indeed, in the recent years different BET protein inhibitors, mimicking 
the acetyl lysines or blocking the bromodomain pocket, have been synthesized  
(Filippakopoulos and Knapp, 2014). The scientific community has extensively taken 
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advantage of BET inhibitors in order to study BETs mechanism of action and their 
involvement in different pathologies.  
 
BETs as cell cycle progression regulators 
BRD2 and BRD4 are the BET proteins better characterized. They are ubiquitously 
expressed, while BRDT expression is limited to the testis. Less is known about BRD3.  
Both BRD2 and BRD4 are involved in the cell cycle control and progression, since BRD2 
interacts with E2F proteins, necessary for S phase genes transcription, and BRD4 is 
recruited on the promoter of G1 genes and it is essential for their expression, since BRD4 
silencing prevents the progression through the cell cycle after serum starvation  
(Mochizuki et al., 2008). Furthermore, BRD4 is also critical for G1/S progression since its 
overexpression led to a block in G1 due to the binding and the sequestration of RFC, a 
component of DNA replication machinery  (Maruyama et al., 2002). Involvement of 
BRD4 was also demonstrated for the G2/M progression, where it is critical the interaction 
with SPA-1, a GAP protein  (Farina et al., 2004). Indeed, not only BRD4 could bind SPA-
1 and enhance its GAP activity, but also SPA-1 could regulate BRD4 subcellular 
localization, since SPA-1 overexpression led to BRD4 mislocalization in the cytoplasm, 
blocking G2/M transition  (Farina et al., 2004). Furthermore, both BRD2  (Shang et al., 
2009) and BRD4  (Houzelstein et al., 2002) deficient mice are not viable, showing severe 
defects in the development and in utero death, respectively. Attempts were made to 
produce BRD2 hypomorphic mice that are still viable but show severe defects in 
organogenesis  (Wang et al., 2010). The drastic in vivo effects caused by deletion of either 
BRD2 or BRD4 clearly suggested that, even though the two proteins share high level of 
homology both in the bromodomains and in the extra-terminal domain, BET proteins 
cannot compensate for the absence of the other family members, thus suggesting that each 
BET protein may have specific and unique functions. 
  Introduction 
18 
 
  
BETs as transcriptional co-activators 
BET proteins are also involved in transcriptional regulation since they can function as co-
activators. BRD4 is involved in the release of the promoter-proximal paused RNA PolII, 
thanks to its ability to recruit pTEFb on the TSS, via the direct binding to Cyclin T1  (Jang 
et al., 2005; Yang et al., 2005). Recent evidences suggested that BRD4 is an atypical 
kinase able to phosphorylate RNA PolII on Ser2. In particular, this activity seems to be 
essential for the first round of RNA PolII phosphorylation, when CDK9 is still repressed  
(Devaiah et al., 2012). Yet, the lack of a clear kinase-like domain in BRD4 protein may 
call into question this atypical BRD4 function.  
BRD4 affects gene transcription both at the promoter-proximal level, thanks to pTEFb 
recruitment, and at distal regulatory regions, through the binding with Jumonji Domain 
containing 6 (JMJD6)  (Liu et al., 2013). The interaction and the cooperation among 
BRD4 and JMJD6 takes place at a subset of distal regulatory regions called anti-pause 
enhancers (A-PE). The looping of A-PE in the proximity of gene promoters, mediated by 
the Mediator complex, ensures the activation of gene transcription thanks to the release of 
promoter-paused RNA PolII. The triggering signal for the release of the RNA PolII is 
mediated by JMJD6, a de-methylase that removes the methyl group from H4R3me2 and 
7SK, thus causing the destabilization of 7SK and the release (and activation) of pTEFb  
(Liu et al., 2013) (Fig.11).  
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Fig. 11 Model for RNA PolII pause release caused by BRD4-JMJD6 interaction 
pTEFb is sequestered in an inactive complex by HEXIM1 and 7SK. When BRD4 and JMJD6, following 
histone acetylation, are recruited on distal regulatory regions, called anti-pause enhancers (A-PE), JMJD6 
enzymatic activity leads to demethylation of both H4R3me2 and 7SK, with the consequent disruption of the 
inhibitory complex. 
Figure adapted from “BRD4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional 
Pause Release”  (Liu et al., 2013) © 2013 Elsevier Inc. 
 
Beside the recognition of acetylated histones, the recruitment of BRD4 on promoters could 
be mediated also by the interaction with specific transcription factors. This TF mediated 
BRD4 recruitment was demonstrated for TWIST target genes  (Shi et al., 2014). Indeed, 
TWIST could recruit BRD4 on the regulatory regions of its targets thanks to the binding of 
TWIST acetylated lysines to BRD4 bromodomains. Once the complex is formed and 
recruited on the chromatin, BRD4 could enhance the transcription of TWIST targets 
recruiting pTEFb  (Shi et al., 2014). In particular, evidences were provided for genes 
involved in the Epithelial to Mesenchymal Transition (EMT) and in tumor progression 
(e.g. WNT5A) (Shi et al., 2014). Furthermore, BRD4 activates the transcription of 
inflammatory genes thanks to interaction with acetylated RelA, a subunit of NFkB. This 
interaction is particularly relevant in tumor where BRD4 stabilizes NFkB in the nucleus, 
allowing the transcription of NFkB targets  (Huang et al., 2009). The involvement of 
BRD4 in the regulation of inflammatory response genes is further supported by the 
demonstration that treatment with BET inhibitors reduces the graft-versus-host disease 
after bone marrow transplantation  (Sun et al., 2015).  
In the scenario of gene transcription regulation, BRD4 can also interact with Nuclear SET 
Domain-Containing Protein 3 (NSD3) via its ET domain  (Rahman et al., 2011). NSD3 is 
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a methyltransferase that belong to the SET family and that is responsible of the 
methylation of the histone H3K36, a histone modification typical of active transcription.  
 
BRD4 is implicated in DNA condensation and gene bookmarking 
Beside its involvement in gene regulation, BRD4 may also have a structural role in 
regulating chromatin condensation. Indeed, studies in which BRD4 was silenced, or 
displaced from the chromatin thanks to the use of a dominant negative isoform, 
highlighted a global chromatin unfolding with a consequent enlargement of the nuclei and 
chromatin fragmentation  (Wang et al., 2012). This effect on chromatin condensation was 
recently connected to a BRD4 role in DNA Damage Response (DDR). Indeed, it was 
demonstrated that BRD4 isoform B is responsible for the maintenance of high order 
chromatin structure and its silencing was associated to an increased γH2AX signal after 
irradiation. The BRD4 isoform B structural function and regulation of DDR seems to be 
mediated by the Condensin II complex and in particular by SMC2 and SMC4, that by 
compacting chromatin can prevent the onset of DDR signaling  (Floyd et al., 2013) . 
Beside the involvement in the transcriptional process and in chromatin structure 
maintenance, BRD4 is also implicated in the transmission of mitotic memory since it is 
constantly bound to chromatin, even during mitosis. BRD4 bookmarking is possible 
thanks to histone acetylation and the consequent binding mediated by the bromodomains. 
Recent publication demonstrated that BRD4 preferentially bound M/G1 genes that showed 
high levels of promoter acetylation. This bookmarking ensures a rapid transcription of G1 
genes soon after the end of mitosis  (Dey et al., 2009; Zhao et al., 2011). The relevance of 
this bookmarking is further supported by BRD4 silencing or inhibition experiments where 
post-mitotic transcription is strongly reduced when BRD4 is evicted from the chromatin  
(Dey et al., 2009; Zhao et al., 2011).  
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Super-enhancers 
In the last few years a new class of distal regulatory regions has been identified: the Super-
Enhancers (SEs). Different features characterize these regions: (1) they are larger than 
canonical enhancers, (2) they are highly acetylated, (3) they show high occupancy of 
transcriptional co-factors such as Mediator complex and BRD4 (4) they are depleted in 
promoters  (Lovén et al., 2013).  
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Fig. 12 Pipeline to define Super Enhancers 
Super Enhancers are defined as broad distal regulatory regions that are particularly enriched for BRD4 and 
MED1 binding, they are highly acetylated and devoid of promoters. After the canonical peak calling 
pipeline, peaks closer than 12.5 kb were stitched together and finally all the stitched peaks are ranked based 
on Med1 enrichment: only the most enriched ones are defined as Super Enanchers.  
Figure adapted from “What are super-enhancers?” (Pott and Lieb, 2015) ©2015 Nature America, Inc. All 
right reserved.  
 
SEs have been computationally identified in different cellular systems and found in the 
proximity of cell identity genes in Embrionic Stem Cells (mESCs)  (Hnisz et al., 2013; 
Whyte et al., 2013) as well as in other differentiated cellular models (pro-B cells  (Meng et 
al., 2014; Qian et al., 2014), adipocytes  (Schmidt et al., 2015). Disruption of the SEs-
promoter loop, through the silencing of Mediator components or by the treatment with 
BRD4 inhibitors, results in the downregulation of these cell type specific genes. SEs can 
be identified not only in physiological conditions but also in cancer cells, where actually 
they were first discovered. In the tumor context, SEs regulate the expression of key 
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oncogenes, as in the MM  (Lovén et al., 2013) or Diffuse Large B Cell Lymphomas 
(DLBCL)  (Chapuy et al., 2013).  
The mechanism of action and the consequent relevance of SEs are still under debate  (Pott 
and Lieb, 2015). The first point of debate is the novelty connected to the SEs since broad 
regulatory regions with enhancer characteristics have been already described as DNA 
Methylation Valleys (DMVs)  (Xie et al., 2013) or Locus Control Regions (LCRs)  (Li et 
al., 2002). Comparison of SEs with DMVs or LCRs showed a high level of overlap, and 
more precisely all the SEs were included in the other categories  (Hnisz et al., 2013). The 
only difference among the distinct classes of the above mentioned distal regulatory regions 
is the number of elements identified, since usually SEs are in the order of hundreds, while 
the others are in the tune of thousands: this difference is probably related to the different 
method used for the identification. Also the approach used to identify SEs is under debate, 
since arbitrary thresholds were used to set the most enriched Med1 stitched peaks. 
Furthermore, functional studies validating the SEs identified are still missing, with the 
consequent confusion about the putative mechanism of action, since it is not clear yet if 
SEs are special regulatory regions with unique characteristics or if their activity is just the 
result of the merging of adjacent canonical enhancers. 
 
BETs misregulation and cancer 
As other factors involved in the cell cycle control, also BRD2 and BRD4 overexpression 
or misregulation is associated with cancer. Indeed, transgenic mice where BRD2 gene is 
placed under the control of the Eµ- enhancer, with a consequent overexpression of the 
gene in the hematopoietic system, are characterized by the onset of lymphomas resembling 
human DLBCL (Greenwald, 2003). The pro-proliferative effect of BRD2 was also 
confirmed by bone marrow (BM) reconstitution experiments, where mice sub-lethally 
irradiated were subjected to BM transplantation with Hematopoietic Stem Cells (HSCs) 
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previously infected with control, overexpressing vectors or silencing vectors for BRD2  
(Belkina et al., 2014). These experiments demonstrated that BRD2 overexpression could 
provide selective advantages to donor B cells and ensured a higher proliferative response 
of mature B cells after stimulation in vitro, while HSCs in which BRD2 was silenced were 
not able to properly engraft and proliferate in the recipient mice  (Belkina et al., 2014).  
Misregulation of BRD4 was first identified in the poorly differentiated squamous cell 
carcinoma, the human NUT midline carcinoma (NMC tumors)  (French et al., 2003) 
where a chromosomal translocation caused the formation of an oncogenic fusion protein 
with BRD4, or most rarely BRD3  (French et al., 2008), and NUT, a nuclear protein 
normally expressed only in testis. This fusion protein is composed of the complete NUT 
protein and the N-terminal domain of BET proteins, including the two bromodomains  
(Filippakopoulos and Knapp, 2014). 
 
Fig. 13 Structure of the BRD-NUT oncogene 
NUT Midline Carcinoma is a poorly differentiated squamous cell carcinoma where BRD4 NTD, comprising 
the 2 bromodomains, is fused to the complete sequence of the NUT protein. More rarely the oncogenic 
fusion protein is composed by BRD3 NTD and NUT protein. 
Figure adapted from “Targeting bromodomains: epigenetic readers of lysine acetylation”  (Filippakopoulos 
and Knapp, 2014) © 2014 Macmillan Publishers Limited. All Rights Reserved. 
 
Recently, a model for “chromatin-driven carcinogenesis” for NMC onset has been 
proposed thanks to the identification of very large regulatory regions called Megadomains  
(Alekseyenko et al., 2015). Briefly, once the BRD-NUT oncoprotein is formed, it binds 
already acetylated regulatory regions that act as “seed” and from which start a feed-
forward loop of acetylation and recruitment of further BRD-NUT proteins, causing the 
spreading of the acetylation and the formation of the Megadomains, whose limits are 
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defined by the Transcription Activation Domains (TADs). The Megadomains are 
associated to enhanced transcription of genes among which are included genes, or non 
coding RNAs, essential for the maintenance of the undifferentiated state characteristic of 
NMC tumors, as Tp63, MED24 and PVT1. These Megadomains differ from the previous 
described SEs  (Lovén et al., 2013) for location and origin, since Megadomains are 
generated from the expansion of already pre-marked and existing canonical enhancers and 
they are an order of magnitude larger than SEs. 
 
Fig. 14 Model for Megadomain formation 
The oncogenic fusion protein BRD4-NUT, after the recruitment on already acetylated chromatin, induces 
further histone acetylation thanks to the binding with p300. The increase in the acetylation levels causes a 
following recruitment of BRD4-NUT protein, the spreading of the acetylation and the formation of the 
megadomain that is limited only by TAD boundaries. 
Figure adapted from “The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within 
large topological domains” (Alekseyenko et al., 2015)  © 2015 Alekseyenko et al.; Published by Cold Spring 
Harbor Laboratory Press. 
 
Inhibiting BET proteins to indirectly targeting Myc 
In the last years an exploding interest on BET proteins rose due to the development of 
small molecules that, preventing the binding of BET proteins to their targets, lead to the 
block of cell proliferation in vitro and tumor regression in vivo. Different reports 
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suggested that Myc downregulation was the principal target of BETs inhibitors, ensuring a 
specificity of action restricted to tumors in which Myc is deregulated  (Dawson et al., 
2011; Delmore et al., 2011; Mertz et al., 2011; Zuber et al., 2011). Since the cellular 
models used in these reports were characterized by different mechanisms accounting for 
Myc deregulation, two distinct models were proposed to explain the specificity of action 
in these different tumor contexts. If c-myc is translocated under the control of the 
Immunoglobulin Heavy chain enhancers (IgH), which are regulatory regions highly 
decorated with BRD4, the reduction in c-myc transcription could be explained by the 
displacement of BRD4 from the IgH enhancers mediated by BETs inhibitors  (Lovén et 
al., 2013).  
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Fig. 15 Model for Myc downregulation mediated by BETs inhibitors in c-myc translocated tumors 
In Multiple Myeloma, as well as in many other hematological malignancies, c-myc is translocated under the 
control of the Immunoglobulin (Ig) regulatory elements. Recently, it was demonstrated that Ig regulatory 
regions are highly decorated with BRD4 and Mediator complex and they differ from the canonical enhancers 
for their length. These new regulatory elements, called IgH Super-enhancers (IgH-SEs), are particularly 
sensitive to BETs inhibition, that evicting BRD4 from IgH SEs, causes a specific switching off of Myc 
expression. 
Figure from “Selective inhibition of tumor oncogenes by disruption of Super-enhancers”  (Lovén et al., 
2013). Copyright © 2013 Elsevier Inc. All rights reserved. 
 
When c-myc is not translocated, as in the Acute Myeloid Leukemia, its expression is 
driven by MLL/AF9 oncoprotein that binds the promoter via BET proteins: in this 
scenario the reduction of Myc expression mediated by BETs inhibitors is due to the lack of 
recruitment of the MLL fusion protein to its promoter.  
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Fig. 16 Model for Myc downregulation in response to BETs inhibition when c-myc expression is 
dependent on other oncogene 
In Acute Myeloid Leukemia the MLL/AF9 fusion protein is the driven oncogene responsible for the 
transcription of genes involved in proliferation and apoptosis as c-myc, BCL2 and others. MLL fusion 
proteins are recruited on the promoters of their targets by BETs proteins. In this context, BETs inhibitors, 
preventing the binding of BET proteins to the acetylated histones, impair MLL fusion proteins transcription 
program. 
Figure adapted from “Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion 
leukaemia”  (Dawson et al., 2011) © 2011 Macmillan Publishers Limited. All Rights Reserved.  
 
Among all the inhibitors produced, the most used in preclinical studies are the ones that, 
mimicking the acetylated lysines, bind the bromodomain with the consequent detachment 
of BET proteins from their interactors (i.e. acetylated histones), as JQ1  (Nicodeme et al., 
2010) and I-BET  (Filippakopoulos et al., 2010).  
  
 
 

  Materials and Methods 
29 
 
III. Materials and methods 
 
Cell culture 
Burkitt’s Lymphoma (BL-2, BL-28, DAUDI, P3HR1, RAJI and RAMOS) and Acute Myeloid 
Leukemia (MV4.11 and THP.1) cell lines were purchased from ATCC. The Multiple Myeloma 
cell lines were kindly provided by Dr. G. Tonon. The Eµ-Myc lymphomas cells were obtained 
smashing lymphomas derived from Eµ-Myc mice. Murine Embryonic Fibroblast (MEFs) were 
derived from 13.5 day post coitum C57/BL6 or MycER knock in embryos. BL, AML and MM 
were cultured in RPMI medium supplemented with 10% Fetal Bovine Serum, 2mM L-
Glutammine, 1% penicillin/streptomycin. Eµ-Myc Lymphoma cells were cultured in DMEM and 
IMDM (ratio 1:1) supplemented with 10% Fetal Bovine Serum, 2mM L-Glutammine, 1% 
penicillin/streptomycin, 25 µM β-mercaptoethanol, 1% Non Essential Aminoacids. MEFs were 
cultures with DMEM medium supplemented with 10% Fetal Bovine Serum, 2mM L-Glutammine, 
1% penicillin/streptomycin, 25 µM β-mercaptoethanol, 1% Non Essential Aminoacids. All the 
cells were grown at 37°C and 5% CO2, except for MEFs that were grown at 37°C in low oxygen.  
For the production of viral particles carrying vectors for constitutive expression, Hek293T or 
AMPHO packaging cells were cultured with DMEM with 10% Fetal Bovine Serum, 2mM L-
Glutammine, 1% penicillin/streptomycin. On the contrary, for the production of viral particles 
carrying vectors for inducible silencing, Hek293T packaging cells were cultured with DMEM with 
10% Tet-FREE Fetal Bovine Serum, 2mM L-Glutammine, 1% penicillin/streptomycin. 
BETs inhibitor JQ1 was kindly provided by Dr. J. Bradner. For the treatment with the drug, 
250000 cells/mL were cultured in fresh medium with different concentration of JQ1 (0, 50, 100, 
250 or 500 nM). 
PHA-767491 (Calbiochem, Cat# 217707) and 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside 
(DRB, Sigma-Aldrich, D1916) were used to inhibit CDK9. 250000 cells/mL were cultured in fresh 
medium and treated with PHA-767491 (0-0.1-1-10-50 µM) or DRB (0-0.1-1-10-100 µM) for 24 or 
3 hours, respectively. 
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Cell transfection, viral production and infection 
Hek293T or AMPHO packaging cells were transfected according to CaCl2 protocol. Briefly, for 
each 10 cm plate of packaging cells, 10 µg of DNA of interest were mixed with 3 µg of helper 
plasmids (VSVG and Δ8.2 for lentiviral production and pKAT or pCL-Eco for retroviral 
production for human or murine cells infection, respectively), 61 µL of CaCl2, 423 µL of H2O and 
500 µL of HBS 2x. The mixture was incubated for 10 minutes at room temperature and then added 
to packaging cells with 9 mL of complete DMEM medium. After O/N incubation, the medium was 
replaced with 5 mL of fresh complete DMEM. The virus was collected 48h and 72h after the 
transfection.  
BL cells were infected using spin infection protocol. Briefly, 2*106 cells were resuspended in 2 mL 
of virus with 8 µg/mL of Polybrene. The cells were spinned at 1800 RPM for 1:30h and then let in 
the incubator at 37°C for 3h. The medium was replaced for the O/N recovery with 2mL of fresh 
complete medium. 24h after the infection, the cells were selected with 2.5 µg/mL of Puromycin. 
When Doxycycline inducible vectors were used, transfection, virus production and cell infected 
culture were performed using medium supplemented with 10% of Fetal Bovine Serum Tet-FREE. 
The induction of the inducible vectors was performed adding 2 µg/µL of Doxycycline. 
 
Plasmids 
LT3GEPIR shREN and RT3GEN shBRD4 were kindly provided by Dr. J. Zuber.  
LT3GEPIR shBRD4 (602-1817-1838) vectors were obtained sub-cloning shRNA targeting BRD4 
from RT3GEN to LT3GEPIR. Briefly, 5 µg of plasmids were digested O/N with XhoI and EcoRI 
restriction enzymes. The digested LT3GEPIR shREN was run on a 0.8% agarose gel, while the 
digested RT3GEN shBRD4 was run on a 2.5% agarose gel. A fragment of 10000 bp for 
LT3GEPIR digestion and one of 150 bp for R3GEN were purified from the gel and quantified by 
nanodrop. Ligation was performed for 3 hours at room temperature using a ratio vector/insert 1:3. 
The ligation was then transformed by heat shock in competent STBL3 bacteria, in order to avoid 
plasmid recombination, and plated on LB+Ampicillin plate. The day after, ~5 single colonies were 
picked and amplified in 5mL of LB+Ampicillin at 37°C over day. 4mL out of 5 mL for each 
bacterial growth were used for plasmid extraction with the NucleoSpin® Plasmid (No Lid) 
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(Macherey-Nagel) according to manufacturer’s instructions. After checking the integrity of the 
plasmids on agarose gel, the vectors with the new insert was then checked by DNA Sanger 
sequencing. 
pBP-CDK9 vector was obtained subcloning CDK9 CDS from pMX-CDK9, kindly provided by 
Dr. M. Esteban, into pBabePuro. Both pMX-CDK9 and pBabePURO were digested O/N with 
BamHI and EcoRI. The fragments were purified after agarose gel run and the ligation was 
performed with 1:3 vector/insert ratio. TOP10 bacteria were then transformed and plated on 
LB+Ampicillin plate for O/N growth. ~5 single colonies were picked and amplified in 5mL of 
liquid LB+Ampicillin at 37°C over day. The vectors were then extracted with the NucleoSpin® 
Plasmid (No Lid) (Macherey-Nagel) according to manufacturer’s instructions. After checking the 
integrity of the plasmids on agarose gel, the vectors with the new insert was then checked by DNA 
Sanger sequencing. 
pBabePURO-EV and pBabePURO-E2F1 were already available in the lab. 
 
Cell growth Assay 
The cell growth was measured using the CellTiterGlo Luminescent Cell Viability Assay 
(Promega).  
For cells that grow in suspension (BL, AML, MM and Eµ-Myc lymphoma cells) 250000 cells/mL 
in a total volume of 4 mL were cultured in 6 well plate in presence of JQ1 (50, 100, 250, 500 nM) 
or DMSO for 4 days. The assay was performed in triplicate every 24h using 100 µL of cell 
suspension and 100 µL of CellTiterGlo. The luminescence was read in a white 96 well plate using 
a multiwell plate reader (Glomax, Promega). 
For adherent cells (MEFs) 500 cells were plated in each well of a white 96 well plate, with a total 
volume of 100 µL. The cells were treated for up to 4 days with DMSO or JQ1 (100 or 250 nM) in 
combination with EtOH or 400 nM of 4-Hydroxytamoxifen (4-OHT). Each condition was plated in 
triplicate and the luminescence was read after the addition of 100 µL of CellTiterGlo using a 
multiwell plate reader (Glomax, Promega). 
Cell cycle and dead cell discrimination analysis 
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The cell cycle progression was analyzed by Bromo deoxy Uridine (BrdU) incorporation. 250000 
cells/mL of BL, AML, MM or Eµ-Myc lymphomas were cultured in a total volume of 15 mL in 
presence of DMSO or JQ1 (100 nM for BL, AML and MM and 50 nM for Eµ-Myc lymphomas) 
for 24h. BrdU (33 µM) was added to the culture during the last 20’ of JQ1 treatment. The cells 
were then collected (1500 RPM for 5’), resuspended with 250 µL of PBS and fixed with 750 µL of 
cold ethanol (100%) dropwise. 500000 cells/ 10 cm plate of MEFs were cultured with DMSO or 
different concentration of JQ1 (100 or 250 nM) in combination with EtOH or 400 nM 4-OHT for 
48h. BrdU (33 µM) was added to the culture during the last 20’ of the treatment. Cells were then 
washed once with PBS, trypsinized and centrifugated at 1500 RPM for 5’. The pellet was 
resuspended with 250 µL of PBS and fixed with 750 µL of cold ethanol (100%) dropwise. For 
both suspension and adherent cells, the fixation step was carrying on O/N at 4°C. The cells were 
then washed once with PBS+1% BSA and then resuspended in 1mL of denaturing solution (2N 
HCl) and incubate at room temperature for 30’. The reaction was blocked with 3mL of 0.1M 
Sodium Borate (Na2B4O7 pH 8.5) for 2 min at room temperature. The cells were then collected at 
1200 RPM for 10’ and washed once with 1mL of PBS+1% BSA. The staining was performed 
using 100 µL of an anti-BrdU mouse antibody (1:5) in PBS 1% BSA for 1h at room temperature 
and light protected. Cells were washed once with 1mL of PBS+1% BSA and resuspended in 100 
µL of anti-mouse FITC (1:50) or anti-mouse Alexa 648 (1:50) in PBS 1% BSA and incubate for 
1h at room temperature, light protected. After one washing step in 1ml PBS 1% BSA, cells were 
incubated O/N at 4°C in 1mL of PBS+PI (2.5 µg/mL) +RNaseA. The acquisitions were performed 
with FACS Calibur. The analysis was performed with FlowJo software. 
The discrimination of dead cells was performed on live BL, AML, MM cells (250000 cells/mL, 
total volume= 10 mL) treated or not with JQ1 (100 nM) for 24h. Cells were collected and washed 
once with 1mL of PBS+1% BSA. Cells were then resuspended in 500 µL of PBS. 2 µL of PI (50 
µg/ml in PBS) were added and incubated for 5’ at room temperature. The acquisitions were 
performed with FACS Calibur. The analyses were performed with FlowJo software.   
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Western blot 
For western blot analysis, 250000 cells/mL of BL, AML, MM and Eµ-Myc lymphoma cells were 
cultured in a total volume of 20 mL. 24h after the plating different concentrations of JQ1 (0, 50, 
100, 250, 500 nM) were added to the culture for either 6 or 24h. Cells were collected by 
centrifugation at 1500 RPM for 5’ and washed once in PBS. Cells were lysed in an adequate 
volume of lysis buffer (20 mM HEPES pH7.5, 100 mM NaCl, 5 mM EDTA, 10% Glycerol, 1% 
Triton X-100) supplemented with MINI-complete Protease Inhibitor Cocktail Tablets (Roche) and 
phosphatase inhibition (0.4 mM ortovanadate, 10 mM NaF) for 10’ on ice. The cell lysate was then 
sonicated for 20’’ with 10% of amplitude with Branson sonicator and cleared by centrifugation at 
full speed at 4°C. Proteins were quantified by Bradford assay. 20-30 µg of proteins were boiled at 
95°C with Laemmli sample buffer and loaded on Mini-PROTEAN® TGX™ Gel (Bio-rad). 
Proteins were transferred to Trans-Blot® Turbo™ Nitrocellulose Transfer Packs (Bio-rad) using 
Trans-Blot® Turbo™ Transfer System (Bio-rad). Blocking was performed with TBS 1X+5% of 
not fat milk or with TBS 1X+ 5% of BSA. The primary antibodies used were: Myc (1:10000, Y69 
Abcam ab32072), vinculin (1:10000, Sigma, V9264), tubulin (1:1000, Santa Cruz), BRD4 
(1:1000, Bethyl A301-985A100), RNA PolII (1:1000, Santa Cruz N-20, sc-899), RNA PolIIS5p 
(1:1000, Abcam ab5131), RNA PolIIS2p (1:500, Chromotek 3e10), HEXIM1 (1:1000, Abcam 
ab25388), CDK9 (1:500, Santa Cruz H-169, sc-8338).  
The secondary antibodies used were: anti-mouse (1:5000, homemade), anti-rabbit (1:5000, 
homemade), anti-rat (1:5000, Cell signaling). The blot were developed with ECL (amsharm) using 
ChemiDoc System (Bio-rad). 
 
RNA extraction and expression quantification 
For expression analysis, 250000 cells/mL of BL, AML, MM and Eµ-Myc lymphoma cells were 
cultured in a total volume of 20 mL, while 500000 cells/10 cm plate were plated for MEFs. 24h 
after the plating different concentrations of JQ1 (0, 50, 100, 250, 500 nM) were added to the 
culture for either 6 or 24h. Cells that grow in suspension were collected by centrifugation at 1500 
RPM for 5’ and washed once in PBS, while adherent cells were trypsinized, centrifugated at 1500 
RPM for 5’ and washed once in PBS. RNA was extracted using RNeasy columns (Qiagen) and 
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treated on-column with DNase (Qiagen). 1 µg of RNA was retrotranscribed using the ImPromII kit 
(Promega) according to the manufacture’s instruction. 10 ng of cDNA were used to perform real-
time qPCR using FAST SYBR Green Master Mix (Applied Biosystems).  
 
Primers: 
Human: 
BRD4 from  (Floyd et al., 2013)  
CDC25A FW:  CACATGGAAGAAGAGGTTGA 
CDC25A REV:  ATACAGCTCAGGGTAGTGGA 
E2F1 FW:  TCCAAGAACCACATCCAGTG 
E2F1 REV:  CTGGGTCAACCCCTCAAG 
GINS3 FW:  AGTCCCGAGAATGCAGACAT 
GINS3 REV:  GCGAAAACGTCCGATAAAAG 
KIF2C FW:  AGGAGCATCTGGTTAACTCTGC 
KIF2C REV:  TCTGCCCAGAGGTTCTGC 
MCM2 FW:  CGAAACCTGGTTGTTGCTG 
MCM2 REV:  GGTGAAGGATTCCGATGATTC 
MYC FW:  TCAAGAGGTGCCACGTCTCC 
MYC REV:  TCTTGGCAGCAGGATAGTCCTT 
PARK7 FW:  GGGGTGAGTGGTACCCAAC 
PARK7 REV:  TGGAAGCCATTTTTATGTTATATGTTT 
RPL36 FW:  GGGCCCTCAAATTTATCAAGA 
RPL36 REV:  GTCTTTCTTGGCAGCAGCTT  
RPPO FW:  TTCATTGTGGGAGCAGAC 
RPPO REV:  CAGCAGTTTCTCCAGAGC 
RRM2 FW:  GCGATTTAGCCAAGAAGTTCAGAT 
RRM2 REV:  CCCAGTCTGCCTTCTTCTTGA 
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SLC16A1 FW:  GTGACCATTGTGGAATGCTG 
SLC16A1 REV  CATGTCATTGAGCCGACCTA 
TOMM20 FW:  CTGCAGGTCTTACAGCAAACTC 
TOMM20 REV: TCAGCCAAGCTCTGAGCAC 
 
Murine: 
Arrsd1 FW:  GCAGAGGCTGTGGAAACC 
Arrsd1 REV:  TTCTTCCCTGCTCCTTTGC 
BRD4 FW:  CCCCATCTCAACCAGCAT 
BRD4 REV:  AGAGCAGCAGCTCGGTTACT 
Cabp4 FW:  GCTGATAAGCCCAAAGCTGA 
Cabp4 REV:  CATCCCTGTCCTTGTCAAACT 
Cct3 FW:  TTAGCTCAGCACTACCTCATGC 
Cct3 REV:  CTCAGGTCGGCTGACTATCC 
Dusp6 FW:  AAATTCCTATCTCGGATCACTGG 
Dusp6 REV:  CATCTATGAAAGAAATGGCCTCA 
Endou FW:  GACGGCTGTCATGAAGGAAC 
Endou REV:  TCGTCCACAAACTCTTGTTCTG 
Fam26f FW:  AGCCTGGTGACCCTACTGAC 
Fam26f REV:  ACTGGAACACCACTGAGGAGA 
Fuca2 FW:  AGTCTGGGGGAAACAGAGGT 
Fuca2 REV:  AGGTAACTCCACGGTGATGC 
Il7r FW:  CGAAACTCCAGAACCCAAGA 
Il7r REV:  AATGGTGACACTTGGCAAGAC 
Msto1 FW:  TACAGAACAGGCCGGACAC 
Msto1 REV:  GGTTACCTTCTTCTTTTAGAGTGTTCA 
Myc FW:  CGTGAACTTCACCAACAGGAAC 
Myc REV:  GAAATTCTCTTCCTCGTCGCAG 
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Myl4 FW:  CAAGCACATCATGTCTGGGTA 
Myl4 REV:  TGGATCTCTTGCTTTCTCACG 
Pax5 FW:  ACGCTGACAGGGATGGTG 
Pax5 REV:  GGGGAACCTCCAAGAATCAT  
Pcbp1 FW:  CAACAGCTCCATGACCAACA 
Pcbp1 REV:  ACCAGCCGAAGTGTGACC 
Pogk FW:  CCAGGGAGTAACCTTTGCAG 
Pogk REV:  GTTGAGGAAAATGGGAGGTG 
Prmt3 FW:  GAGGATGAGGATGGCGTCTA 
Prmt3 REV:  ACTTTCTGTGCGTACTTTGTCCT 
Pus7 FW:  CCCCAAGCATAAAATCAGTGAGG 
Pus7 REV:  CCCCGATAAGGAGTAATCTCGAA 
Reep6 FW:  AGCGCTTCGAACGTTTTCT 
Reep6 REV:  TCTCTACACCGGTCCTTGCT 
Rppo FW:  TTCATTGTGGGAGCAGAC 
Rppo REV:  CAGCAGTTTCTCCAGAGC 
Rsph9 FW:  ACCACGCAAGACGCTCTAC 
Rsph9 REV:  AACGGCCACTCACCACAG 
Slc16a13 FW:  ACCTGAGTATTGGGCTGCTG 
Slc16a13 REV:  GCCATGGTCGGAGTGAAG 
 
For Microarray assay, 250000 cells/mL of RAJI cells were cultured in a total volume of 40 mL. 
24h after the plating DMSO or 100 nM of JQ1 were added to the culture for 24h. Total RNA from 
107 RAJI was purified using TRIzol reagent (Invitrogen) according to manufacturer’s instructions, 
treated with TurboDNase (Ambion) and processed for oligonucleotide microarray profile through 
Affymetrix Human Gene 1.0 ST arrays platform.  
For RNAseq assay, 250000 cells/mL of Eµ-Myc lymphoma cells (ly9644, ly27805, ly28514) were 
cultured in a total volume of 40 mL. 24h after the plating DMSO or 50 nM of JQ1 were added to 
the culture for additional 24h. Total RNA was extracted from 107 Eµ-Myc lymphoma cells using 
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miRNeasy Mini Kit (QIAGEN) according to manufacturer’s instructions. Digestion with DNase I 
was performed on column. 1 µg of RNA was used for RNAseq strand specific library preparation 
(Illumina) according to TruSeq Stranded Total RNA Sample Preparation Guide. Ribosomal RNA 
was removed using rRNA removal Mix, present in the kit. The index used to mark the different 
samples was decided according to TruSeq Sample Preparation Pooling Guide (Illumina): since we 
multiplexed 2 samples per lane, we used AR006 and AR012 to mark DMSO and JQ1 samples, 
respectively. The efficacy of rRNA depletion and the quality of the library preparation were tested 
using Agilent Technologies 2100 Bioanalyzer using Eukaryote Total RNA Nano or High 
Sensitivity DNA Assay, respectively. 
Nanostring® assay was performed using a codeset designed including genes deregulated by Myc. 
Briefly, 250000 cells/mL of Eµ-Myc lymphoma cells (ly9644, ly27805, ly28514) were cultured in 
a total volume of 40 mL. 24h after the plating DMSO or 50 nM of JQ1 were added to the culture 
for additional 24h. Total RNA was extracted from 107 Eµ-Myc lymphoma cells using TRIZOL 
reagent (Invitrogen) according to manufacturer’s instructions and treated with TurboDNase 
(Ambion).100 ng of total RNA was used to proceed with the probe hybridization according to 
manufacturer’s instructions. 
 
4-sU labeling 
4-thiouridine (4-sU) labeling was performed as previously described (Rabani et al., 2011) with 
minor modifications. RAJI (300000 cells/mL) were cultured in 100 mL of complete medium. 24h 
after the plating, cells were treated with vehicle (DMSO) or JQ1 (100 nM) for 24h. A pulse of 30’ 
of 4-sU (300 µM) was performed. The reaction was immediately blocked with 4 volumes of cold 
PBS and cells were centrifugated at 1800 RPM for 15’ at +4°C. RNA was extracted with the 
Qiagen miRNeasy kit according to the manufacturer’s instructions and DNase I digestion was 
performed. 40 µg of total RNA was used for the biotinylation reaction. RNA was diluted in 100 µl 
of RNase-free water. 100 µl of biotinylation buffer (2.53 stock: 25 mM Tris pH 7.4, 2.5 mM 
EDTA) and 50 µl of EZ-link biotin-HPDP (1 mg/ ml in DMF; Pierce/Thermo Scientific 21341) 
were added and incubated for 2 h at 25°C. RNA was precipitated and unbound biotin-HPDP was 
removed by a combination of chloroform/isoamylalcohol (24:1) precipitation with purification 
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using MaXtract high density tubes from Qiagen. Biotinylated RNA was purified using Dynabeads 
MyOne Streptavidin T1 (Invitrogen). Before addition of RNA, 50 µL of beads were washed twice 
in washing buffer A (100 mM NaOH, 50 mM NaCl) and once in washing buffer B (100 mM 
NaCl). Beads were resuspended in 100 µL of buffer C (2 M NaCl, 10 mM Tris pH 7.5, 1 mM 
EDTA, 0.1% Tween-20) to a final concentration of 5 µg/µL. RNA was added in an equal volume 
and rotated at room temperature for 15’. Beads were washed 3 times with washing buffer C. RNA 
was eluted from the beads in 100 µL of 10 mM EDTA in 95% formamide (65 °C, 10'). RNA was 
extracted with the RNeasy MinElute Spin columns from Qiagen according to the manufacturer and 
eluted in 14 µL of RNase-free water. RNA was retrotranscribed with SuperScript® VILO cDNA 
Synthesis Kit, according to manufacturer’s instruction. Real-time qPCR was performed using 
FAST SYBR Green Master Mix (Applied Biosystems). 
 
Primers: 
MCM2 FW 
AAGGGGATTGTCTTGGGGAG 2°intron  
MCM2 REV TGCCTATGGTCGCTCTGTAG 2° intron 
MCM2 FW CCATTCTTGTCGGTCTCCCT 7°intron-8°exon 
MCM2 REV CCAGGCCTCTCTTGATGTCT 7°intron-8°exon 
RPL36 FW TACTCACCTCCGCCCCTT 1° exon 
RPL36 REV CACTTTGTGGCCCTTGTTGA 1° exon 
RPL36 FW CGCGAGAGAAGCTGCTTAAC 2°intron-3°exon 
RPL36 REV GTGTTTGGTCAGACGCTAGG 2°intron-3°exon 
RRM2 FW AGTGGTGTGATCTTGGCTCA 4°intron 
RRM2 REV ACTCATGAGGCTGAGGTTGG 4°intron 
RRM2 FW TGTGACTTCCGAACCTCAGG 3°intron-4°exon 
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RRM2 REV CTCCTCGGGTTTCAGGGATT 3°intron-4°exon 
SYVN1 FW CTGGAACCTGGGTCAGTCTT 1° intron 
SYVN1 REV TGCAGCTTTTCCTCATCACC 1° intron 
SYVN1 FW ATTCAAGGCACATGTGGGGT 6°exon-7°intron 
SYVN1 REV CTGGTGTTTGGCTTTGAGGT 6°exon-7°intron 
TOMM20 FW AGCCTGGTTGATACGGTGAA 1° intron 
TOMM20 REV GCCTCTCGAGTAGCTAGGAC 1° intron 
TOMM20 FW GATGGTCTACGCCCTTCTCA 3°intro-4°exon 
TOMM20 REV CCAAGGCTTTTCAGGTTACATG 3°intro-4°exon 
ZNF367 FW CCAGCCCCAGTGAAGAAGTA 1°intron 
ZNF367 REV CAAGTTGTTCCAAGGCTCCC 1°intron 
ZNF367 FW CACAGATAGGGCCTCTCACC 2°intron-3°exon 
ZNF367 REV CCCTCCTCTTCTGGCCTTAT 2°intron-3°exon 
 
  
 
Chromatin Immunoprecipitation 
BL, MM or Eµ-Myc lymphoma cells (250000 cells/mL) were plated and DMSO or JQ1 (100 nM 
for the cell lines, 50 nM for Eµ-Myc lymphomas) were added 24h after the initial plating. After 
24h of drug treatment, cells were counted and washed once with PBS. 108 cells were resuspended 
in 10 mL PBS and fixed. For Myc, Histone Marks, RNA PolII and E2F1 ChIP the cells were fixed 
using formaldehyde (final concentration of 1%), for BRD4 ChIP the cells were fixed using either 
glutaraldehyde (final concentration 1%) or formaldehyde (final concentration of 1%). The fixation 
step was carried out at room temperature for 10’ and quenched with 0.125 M Glycine for 5’ at 
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room temperature. Cells were washed twice with PBS and stored at -80°C as pellet. 108 cells were 
resuspended in 5 mL of LB1 buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% 
Glycerol, 0.5% NP-40, 0.25% Triton X-100), kept on ice for 10’ and then centrifugated at 1350 xg 
for 5’ at +4°C. The supernatant was eliminated and the cells were gently rocked at room 
temperature for 10’ in 5 mL of LB2 buffer (10 mM tris-HCl pH 8, 200 mM NaCl, 1 mM EDTA, 
0.5 mM EGTA). At this point, the nuclei were extracted and pelleted by spinning at 1350 xg for 5’ 
at +4°C. The pellet was resuspended in 3 mL of LB3 buffer (10 mM Tris-HCl pH 8, 100 mM 
NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1 % Na-Deoxycholate, 0.5% N-lauroylsarcosine) and 
sonicated in order to obtain DNA fragment of 300-100 bp. For BRD4, Myc, E2F1, total RNA PolII 
and RNA PolII-S5p ChIP, the lysate from 50*106 cells was incubated with 10 µg of antibody 
previously bound to protein G Dynabeads (Invitrogen) in PBS+0.5% BSA. For Histone Marks 
ChIP, 20*106 cells were incubated with 5 µg of the antibody previously bound to protein G 
Dynabeads (Invitrogen) in PBS+0.5% BSA. For RNA PolII-S2p ChIP, the lysate corresponding to 
10*10 7 cells was incubated with 60 µL of hybridoma O/N on the rotating wheel at +4°C. 
Concomitantly, 4.5 µL of anti-rat were incubated with 50 µL of protein G Dynabeads O/N on the 
rotating wheel at +4°C. The day after the chromatin+primary antibody was mixed to the secondary 
antibody+protein G Dynabeads for 3h on rotating wheel at +4°C. After the incubation with the 
antibody, the beads were collected using the DynaMag™ magnet and washed 6 times with 1 mL of 
RIPA buffer (50 mM HEPES pH 7.5, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-
Deoxycholate). Beads were then washed with 1 mL f TE 1X+50 mM NaCl before the elution step 
(de-crosslinking). For cells fixed with formaldehyde, de-crosslinking was performed O/N at 65°C 
with 150 µL of TE1X+2% SDS. For cells fixed with glutaraldehyde, de-crosslinking was 
performed with 150 µL of TE+1% SDS+ 100 mM NaHCO3. The sample were first treated for 1h 
with RNaseA at 37°C, then Proteinase K was added and the de-crosslink reaction was incubated at 
65°C O/N. DNA was purified with PCR Qiaquick columns (Qiagen) and quantified using 
PicoGreen (Invitrogen) or QUBIT (Invitrogen). 
For ChIPqPCR, 6 µL of DNA diluted 1:6 was used to perform real-time PCR using FAST SYBR 
Green Master Mix (Applied Biosystems).  
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Primers: 
Human: 
AchR FW:  CCTTCATTGGGATCACCACG 
AchR REV:  AGGAGATGAGTACCAGCAGGTTG 
IFRD2 FW:  CGTGCCCCAGCAGTCATT 
IFRD2 REV:  GCAGTGGGCAGCGAGC 
IgH_E1, IgH_E2, IgH_E3, IgH_E4 primers were taken from  (Delmore et al., 2011)  
NCL FW:  TTTTGCGACGCGTACGAG 
NCL REV:  ACTAGGGCCGATACCGCC 
NME1 FW:  GGGAGTGGGTTAGGTGAGGAGT 
NME1 REV:  CGTCGCGGTCTGACGAG 
 
Murine: 
AchR FW:  AGTGCCCCCTGCTGTCAGT 
AchR REV:  CCCTTTCCTGGTGCCAAGA 
D7 FW:  CGGCTCGGCCAGCAGAAG 
D7 REV:  TAGTCCACATGGCGGCGC 
Nucleolin FW:  GAGTGTCTGTAGTACCCCGGAAA 
Nucleolin REV: CCACGCTGCCGTCCC 
Pus7 FW:  GCTGCACCGCGTGGAGAC 
Pus7 REV:  GGCTGGTGGGATAACCCGT 
For ChIPseq, 2–10 ng ChIP DNA was prepared for HiSeq2000 sequencing with TruSeq ChIP 
Sample Prep Kit (Illumina) following the manufacturer’s instructions. 
 
 
 
NGS data filtering and quality assessment 
ChIP-seq reads sequenced with the Illumina HiSeq2000 were filtered using the fastq_quality_ 
trimmer (setting the options to -Q33 -t 20 -l 10) and fastq_masker (setting the options to -q 20 -r 
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N) tools of the FASTX-Toolkit suite (http://hannonlab. cshl.edu/fastx_toolkit/). Their quality was 
evaluated and confirmed using the FastQC application 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  
 
Analysis of ChIP-seq data 
ChIP-seq NGS reads were aligned with the BWA tool (Li H. (2013) Aligning sequence reads, 
clone sequences and assembly contigs with BWA-MEM.arXiv:1303.3997v2 [q-bio.GN].) using 
default settings using the mm9, hg19 and hg18 genomes for Eμ-myc, Raji and MM1.S and OC-
LY1 data, respectively. Peaks were called with the MACS v1.4 software  (Zhang et al., 2008) . 
Peaks’ p-value threshold was set to 10-8 for Raji data and 10-9 for MM1.S data. FDR (false 
discovery rate), determined as the ratio between the negative and the positive peaks, was set to 5% 
for all the data. Negative peaks were found by MACS on the input samples, using the ChIP as 
reference.  
Normalized reads count within a genomic region was determined as the number of reads per 
million of library aligned reads (rpm), that were subtracted by the input normalized reads. Peak 
read density (reads per million of reads per base pair) for a particular region was determined as the 
ratio between the normalized reads count and the length of the region in base pair. 
 
Definition of promoter, intragenic and intergenic regions 
In order to assess if a specific ChIP-seq peak is in a promoter, in a genebody or is intergenic, the 
following criteria were applied. Regions that overlap with at least one bp with any promoter 
(defined as genomic region [-2000; +1000] bp spanning TSSs, transcription start sites), were 
considered as belonging to promoters; regions that weren’t promoters but had at least 1 bp 
overlapping with any genebody were considered intragenic. The remaining regions (that did not 
overlap either with promoters or genebodies) were considered intergenic. Annotations were 
performed with the R annotation packages TxDb.Hsapiens.UCSC.hg19.knownGene and 
TxDb.Hsapiens.UCSC.hg18.knownGene or TxDb.Mmusculus.UCSC.mm9.KnownGene of 
Bioconductor(Marc Carlson (). TxDb.Hsapiens.UCSC.hg18.knownGene: Annotation package for 
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TranscriptDb object(s). R package version 2.14.0.; Marc Carlson (). 
TxDb.Hsapiens.UCSC.hg19.knownGene: Annotation package for transcriptDb object(s). R 
package version 2.14.0.). 
 
RNA PolII stalling index 
The RNA polymerase II stalling index (SI, also called elongation rate) (Rahl et al., 2010; 
Zeitlinger et al., 2007) was calculated as SI = Prom/GB; prom refers to the read counts on the 
promoter (TSS ± 300 bp interval) and GB to the read counts in the gene body (the interval between 
TSS +301 and 3,000 bp after the TSS). These values were normalized both to library size (total 
number of reads) and to the length of the interval, and only genes with GB > 600 and with a 
RNAPII ChIP-seq peak in the promoter region were considered. PolII signal in genebodies was 
plotted using the same criteria that were used in SI calculation; genes were expanded by 20% 
upstream and 20% downstream, in order to have a better overview of the neighborhood. They were 
then divided into 150 bins, for which the input-subtracted reads were counted and were normalized 
both by library size and gene length, using “GRcoverageInbins” function of compEpiTools R 
package (http://genomics.iit.it/groups/computational-epigenomics.html (2014). compEpiTools: 
tools for computational epigenomics. R package version 0.99.0.). 
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IV. Results 
 
BET inhibition effects on cell viability and Myc levels 
Previous publications already showed that BET inhibition strongly affects the proliferation of 
different tumor types (e.g. Multiple Myeloma (MM), Acute Myeloid Leukemia(AML)) both in 
vitro and in vivo  (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011; Zuber et al., 
2011). We focused our attention on human Burkitt’s lymphoma (BL) cell lines and on Eµ-Myc 
lymphomas, a murine model for immature B cells malignancies  (Adams et al., 1985). BL are 
characterized by a chromosomal rearrangement that put in close proximity the c-myc locus and the 
immunoglobulin distal regulatory regions. The most common recombination involves chromosome 
8, where the c-myc gene is located, and chromosome 14, containing the regulatory regions for the 
immunoglobulin heavy chain (IgH). In a minor fraction of BL cases, c-myc is juxtaposed to the 
immunoglobulin light chain regulatory regions in chromosome 2 or 22  (Molyneux et al., 2012). 
The Eµ-Myc mouse model was engineered in the ‘80s to mimic human B cell malignancies: in this 
murine model, the chromosomal rearrangement found in the plasmacytoma ABPC17  (Corcoran et 
al., 1985) was reproduced fusing the IgH enhancer upstream of the first exon of the c-myc gene. In 
this model, c-myc misregulation leads to the development of B cell lymphoma with a short latency 
of around 3 months and high penetrance.  
As a first step, we assessed the sensitivity of BL and Eµ-Myc lymphomas cells to BET inhibition, 
by evaluating cell growth in samples treated with increasing doses of JQ1, ranging from 50 nM to 
500 nM. As positive controls, we used AML (MV4.11, THP.1) and MM cells (MM.1S, OPM1, 
KMS11) for which the sensitivity to BETs inhibitors has already been reported. As shown in 
Fig.17, all the BL cell lines (BL-2, BL-28, DAUDI, P3HR1, RAJI and RAMOS) and Eµ-Myc 
lymphoma cells were responsive to BET inhibition, showing growth arrest in a time- and dose-
dependent manner. RAJI and Eµ-Myc lymphomas were the most sensitive cells, since they showed 
a strong decrease in cell viability already after 48h of treatment, at relatively low doses of JQ1 
(100 nM and 50 nM, respectively).  
  Results 
 
 
45 
 
Fig. 17 BETs inhibition strongly affects cell growth 
Cell growth assay using CellTiterGlo (Promega) on BL (BL-2, BL-28, DAUDI, P3HR1, RAJI and 
RAMOS), three independent Eµ-Myc lymphomas (9644, 27805 and 28514), MM (MM.1S, OPM1, KMS11) 
and AML (MV4.11, THP.1) cell lines after treatment with 0-50-100-250-500 nM JQ1 for up to 4 days. For 
each time point, the mean and the standard deviations of 3 technical replicates are reported.  
 
Since BET inhibition caused a strong decrease in cell growth, we wondered whether this effect 
was due to a block in the cell cycle progression, to an increase in cell death or both. In order to 
discriminate among these possibilities and to evaluate short-term responses, we performed cell 
cycle analysis on cells treated for 24h using the lowest effective dose of JQ1, as determined in the 
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experiments mentioned above. In particular, 100 nM of BETs inhibitor was used to treat the 
human cell lines (BL, AML and MM), while 50 nM was used for Eµ-Myc lymphomas treatment. 
As shown in Fig.18, in BL and Eµ-Myc cells, BETs inhibition led to a decrease in the percentage 
of cells in S phase with a consequent increase in the G0/G1 population, suggesting a defect in 
G1/S progression. Also from this type of assay, RAJI and Eµ-Myc lymphomas resulted the most 
sensitive cell lines to BETs inhibition. Indeed, for RAJI cells the S-phase population dropped from 
42% to 10%, while the G0/G1 population increased from 38% to 78%. Similar results were 
observed for Eµ-Myc lymphomas were the percentage of BrdU positive cells diminished from 
68% to 40%, with a concomitant increase of G0/G1 population (from 23.5% to 45.2%). The 
reduction in the percentage of cycling cells was evident also in the other BL cell lines (BL-2, 
DAUDI, P3HR1 and RAMOS), even though they showed a milder cell cycle alteration with a 
~20% reduction of the S-phase population respect to the control condition (from ~50-40% in 
DMSO sample to ~40-30% in JQ1 sample). The only exception was represented by BL-28 cells 
that, after 24h of treatment did not show any alteration in the cell cycle distribution. This was 
expected and coherent with the low sensitivity of BL-28 to BET inhibition observed in the cell 
growth assay. 
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Fig. 18 BETs inhibition alters cell cycle progression 
Cell cycle analysis by BrdU incorporation in BL (BL-2,BL-28, DAUDI, P3HR1, RAJI, RAMOS), Eµ-Myc 
lymphoma, MM (MM.1S, OPM1, KMS11) and AML (MV4.11, THP.1) cells after treatment for 24h with 
DMSO or JQ1 (100 nM for human cell lines or 50 nM JQ1 for Eµ-Myc cells). A BrdU pulse of 20’ was 
performed. DNA content is evaluated by PI staining. For each cell line a single technical replicate was 
performed once. 
 
In order to verify if the decrease in the percentage of cells engaged in active cell division was also 
associated to an increase in the amount of cellular death, we assessed cell vitality after 24h of 
treatment with BETs inhibitor, using Propidium Iodide (PI) staining as readout. As shown in the 
Fig.19, the different cell lines used showed a different percentage of PI positive cells in the control 
sample, reflecting intrinsic characteristics of each cell line. However, the treatment with JQ1 did 
not influence the amount of PI positive cells since it remained constant both in DMSO and JQ1 
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treated sample, suggesting the absence of any toxic effect mediated by BETs inhibition, at least in 
the first 24h.  
Comprehensively, the analysis of cell growth and the vitality assay suggested that the first 
response to BETs inhibitors was mainly cytostatic with limited cytotoxic effects. 
 
Fig. 19 BETs inhibition does not increase cellular death 
Analysis of cell vitality on BL (BL-2, BL-28, DAUDI, P3HR1, RAJI, RAMOS), MM (MM.1S, OPM1, 
KMS11) and AML (MV4.11, THP.1) cells after treatment for 24h with DMSO or 100 nM JQ1 through PI 
incorporation. For each cell line a single technical replicate was performed. 
 
The lack of a strong impact on cell death was further confirmed by experiments on Eµ-Myc cells 
infected with a constitutive vector encoding for BCL2, in order to make an apoptosis resistant 
version of these lymphomas. Two independent Eµ-Myc lymphomas infected with MSCV-BCL2 or 
MSCV-EV (as control) were treated with vehicle (DMSO) or 50 nM of JQ1 for up to 4 days and 
cell growth analysis was performed. As shown in Fig.20, the overexpression of BCL2, while 
providing increased fitness of the lymphomas, did not alter the effects of JQ1, since at all time 
point considered we observed a consistent inhibition of cell growth. 
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Fig. 20 BCL2 overexpression does not impact on the impairment of cell growth mediated by JQ1 
Cell growth assay using CellTiterGlo (Promega) on two independent Eµ-Myc lymphomas (21112 and 
23600) infected with MSCV-BCL2, or MSCV-EV as control, and treated with DMSO or 50 nM of JQ1 for 
up to 4 days. The mean and the standard deviations of 3 technical replicates are reported for each time point.  
 
As expected, overexpression of BCL2 had no effect on cell cycle distribution: both control and 
BCL2 overexpressing lymphomas responded to BETs inhibition with a decrease in the percentage 
of S-phase cells (from ~60-50% in DMSO to ~30% in JQ1 sample) and a consequent increase in 
the amount of cells in G1 (from ~30-40% in DMSO to ~50-60% in JQ1) (Fig.21). 
 
Fig. 21 Bypass of apoptosis is not influencing cell cycle distribution after BETs inhibition 
Cell cycle analysis after BrdU incorporation in two independent Eµ-Myc lymphomas (21112 and 23600) 
infected MSCV-BCL2, or MSCV-EV as control, and treated with DMSO or 50 nM of JQ1 for 24h. DNA 
content is evaluated through PI staining. For each Eµ-Myc lymphoma a single technical replicate was 
performed. 
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The strong cytostatic effect observed is in line with what reported by studies on MM and AML  
(Delmore et al., 2011; Mertz et al., 2011; Zuber et al., 2011) where cell cycle arrest following 
BETs inhibition was linked to Myc downregulation. In order to verify if the decrease in c-myc 
expression after BETs inhibition was shared by different cellular systems, we analyzed Myc 
expression in BL and Eµ-Myc cells after JQ1 treatment, investigating both RNA and protein levels 
by RTqPCR and Western Blot, respectively. As previously reported  (Delmore et al., 2011; Mertz 
et al., 2011; Zuber et al., 2011), we observed a substantial drop in Myc levels both at the RNA 
(Fig.22) and protein levels (Fig.23) either in MM and in AML cell lines. Myc downregulation was 
not consistently observed in all the BL cell lines analyzed: indeed, while BL-28, DAUDI and 
RAMOS showed a reduction in Myc transcription in a dose-dependent fashion; BL-2, P3HR1 and 
RAJI showed Myc mRNA changes only when treated with the highest concentration of JQ1 (500 
nM) (Fig.22). The analysis of Myc protein levels phenocopied the expression data, since we 
observed Myc reduction in BL-2, P3HR1 and RAJI only after treatment with the highest 
concentration of drug (Fig.23). Similarly to what observed for some BL cell lines, also Eµ-Myc 
lymphomas did not show any changes in Myc mRNA (Fig.22) or protein (Fig.23) levels after 24h 
of BETs inhibitor treatment. These experiments suggested that JQ1 has growth inhibitory 
properties that can be separated from its effect on the modulation of Myc levels. 
 
Fig. 22 BETs inhibition is not always associated to a reduction of Myc mRNA 
Analysis of Myc expression levels by RTqPCR on BL (BL-2, BL-28, DAUDI, P3HR1, RAJI and RAMOS), 
three independent Eµ-Myc lymphomas (9644, 27805 and 28514), MM (MM.1S, OMP1, KMS11) and AML 
(THP.1, MV4.11) cells treated for 24h with different concentrations of JQ1 (black: DMSO, red: 50 nM, 
orange: 100 nM, yellow: 500 nM). The expression values are normalized on RPP0 and DMSO sample. The 
mean and the standard deviations of 3 technical replicates are reported. 
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Fig. 23 BETs inhibition is not always associated to a reduction of Myc protein 
Analysis of Myc protein levels by Western Blot analysis on BL (BL-2, BL-28, DAUDI, P3HR1, RAJI and 
RAMOS), three independent Eµ-Myc lymphomas (9644, 27805 and 28514), MM (MM.1S, OMP1, KMS11) 
and AML (THP.1, MV4.11) cells treated with different concentrations of JQ1 (0-50-100-500 nM) for 6 or 
24h. Vinculin or tubulin is used as loading control. Quantification of Myc signal over Vinculin or Tubulin 
one is shown in the barplots. For RAJI cell line, 1 technical replicate for 3 independent biological replicates 
were performed and a representative western blot is shown. For the remaining cell lines, a single technical 
replicate was performed. 
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MM cell lines are characterized by a chromosomal translocation that juxtaposes the c-myc locus to 
the immunoglobulin heavy chain (IgH) regulatory regions. These IgH enhancers are characterized 
by extremely high BRD4 binding that positively regulates the transcription of the translocated c-
myc  (Lovén et al., 2013). In this light, Myc downregulation in response to JQ1 treatment could be 
explained as a consequence of BRD4 displacement from IgH enhancers. Since also BL are 
characterized by chromosomal rearrangement involving the c-myc gene and Ig regulatory 
elements, we asked if the lack of Myc downregulation in response to BETs inhibition, that we 
observed in some BL cell lines, could be dependent on different chromatin modifications of the 
IgH enhancers. To test this hypothesis, we performed Chromatin Immuno-Precipitation followed 
by quantitative PCR (ChIPqPCR) experiments on the IgH regulatory regions for H3K27Ac 
(Fig.24), commonly used as mark of open and active chromatin. The levels of acetylation were 
comparable among all the cell lines used, with the only exception for BL-28 that did not show any 
acetylation in the IgH enhancers (Fig.24).  
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Fig. 24 Analysis of the acetylation levels on the IgH regulatory regions 
Analysis of histone H3 acetylation levels on IgH regulatory regions by ChIPqPCR for H3K27Ac on BL 
(BL-2, BL-28, DAUDI, P3HR1, RAJI, RAMOS) and MM.1s treated with DMSO (black) or 100 nM of JQ1 
(red) for 24h. The mean and the standard deviations of 3 technical replicates are reported. Acetylcholine 
Receptor (AchR) is used as negative control. 
 
Since previous works on MM cells showed that IgH enhancers are particularly enriched for BRD4 
binding, we verified if also BL IgH enhancers were decorated with BRD4 and if there were 
differences in terms of binding intensity or response to JQ1 treatment that could account for the 
absence of Myc downregulation observed in particular in RAJI. As it is shown in Fig.25, BL and 
MM cell lines were characterized by different levels of BRD4 binding to the IgH enhancers. In 
general, BL cells showed a lower BRD4 signal on the IgH enhancer regions compared to MM 
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lines. In particular, for 3 out of 6 BL cell lines used (BL-28, P3HR1, RAJI), BRD4 binding at the 
IgH enhancers was undetectable, while for the remaining 3 (BL-2, DAUDI, RAMOS) BL cell 
lines, BRD4 signal was barely enriched respect to the negative control, with a signal intensity that 
was from 5 to 10 times lower than the one determined in MM lines. Furthermore, BRD4 binding 
was strongly reduced in MM cells after JQ1 treatment, confirming the efficacy of the drug.  
Interestingly, no BRD4 could be detected on the IgH enhancers of P3HR1 or RAJI, possibly 
accounting for their lack of Myc downregulation following BET inhibition. 
 
 
Fig. 25 BL cells are characterized by low levels of BRD4 binding on IgH enhancers 
Analysis of BRD4 binding on IgH regulatory regions by ChIPqPCR for BRD4 on BL (BL-28,DAUDI, 
P3HR1, RAJI, RAMOS) and MM (MM.1S, KMS11) treated with DMSO (black) or 100 nM of JQ1 (red) for 
24h. The mean and the standard deviations of 3 technical replicates are reported. Acetylcholine Receptor 
(AchR) is used as negative control. 
 
The evidences collected so far suggested that MM and BL cell lines, despite the similar 
chromosomal rearrangement, control c-myc expression differently. Indeed, while the strong 
downregulation of Myc in MM cells could be explained by the massive depletion of BRD4 from 
the IgH enhancers, in BL cells other BRD4-independent regulatory mechanisms should account 
for Myc regulation, since the low BRD4 binding on IgH enhancers and the lack of transcriptional 
effect on Myc after JQ1 treatment.  
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JQ1 effects are mainly mediated by BRD4 
While JQ1 shows high affinity for BRD4, it also has some potential activity on other 
members of the BET family  (Filippakopoulos et al., 2010). To gain some insight 
regarding the intracellular target of JQ1, we first evaluated the expression of the 3 main 
BET proteins expressed in somatic tissue by RTqPCR. While BRD3 is barely expressed in 
all the cell lines analyzed (BL, MM and Eµ-Myc lymphomas), BRD4 is the predominant 
BET protein expressed in BL and MM cell lines. Instead, in the Eµ-Myc system, both 
BRD2 and BRD4 are present at comparable levels (Fig.26).   
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Fig. 26 BRD2 and BRD4, but not BRD3, are expressed in BL, Eµ-Myc lymphomas and MM 
Analysis of BETs proteins expression levels by RTqPCR for BRD2 (black), BRD3 (dark grey) and BRD4 
(light grey) in BL (BL-2, BL-28, DAUDI, P3HR1, RAJI), Eµ-Myc lymphomas (9644, 27805 and 28514) 
and MM (MM.1S, OPM1, KMS11). The expression values are normalized to RPP0 levels. The mean and the 
standard deviations of 3 technical replicates are reported. 
 
Since JQ1 causes the displacement of its target from the acetylated histones, we evaluated the 
chromatin occupancy of BET proteins performing ChIPqPCR for BRD2, BRD3 and BRD4 on the 
TSS of genes selected (Fig.27). While both RAJI and Eµ-Myc cells showed no BRD3 enrichment 
compared to the negative control (Acetylcholine Receptor: AchR), as expected since the very low 
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expression level, the other two members of the family, BRD2 and BRD4, were bound to the TSS 
of the genes analyzed.  
 
 
Fig. 27 BRD2 and BRD4, but not BRD3, bind promoters of active genes. 
Analysis of BRD2 (black), BRD3 (dark grey) and BRD4 (light grey) chromatin binding by ChIPqPCR for 
on the promoter of expressed genes on RAJI or Eµ-Myc lymphomas. Acetylcholine Receptor (AchR) is used 
as negative control. For each cell line a single technical replicate was performed. 
 
This results were in line with already published ChIPseq experiments on MM.1S cells for all the 
BET proteins  (Anders et al., 2014). Indeed, these genome wide data showed that the 3 family 
members co-occupied the same genomic regions and furthermore, BRD4 signal was stronger and 
more abundant respect to BRD2 or BRD3 ones. After verifying the expression and the chromatin 
binding of BET proteins, we tested if BRD2 and BRD4 are equally affected by the treatment with 
JQ1, performing ChIPqPCR for BRD2 or BRD4 on RAJI or Eµ-Myc lymphomas after the 
treatment with DMSO or JQ1 for 24h (Fig.28). While BRD4 was consistently displaced after JQ1 
treatment in all the cellular models analyzed, BRD2 response was more heterogeneous since just 
one Eµ-Myc lymphoma (28514) out of 3 showed a strong reduction in BRD2 enrichment after 
BET inhibition, thus suggesting that the cytostatic effect observed upon JQ1 administration was 
mainly due to BRD4 inhibition.  
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Fig. 28 JQ1 displaces BRD4, and less efficiently BRD2, from chromatin 
Analysis of BRD2 or BRD4 binding to the chromatin after DMSO (black) or JQ1 (red) treatment through 
ChIPqPCR on RAJI or Eµ-Myc lymphomas (9644, 27805 and 28514). Acetylcholine Receptor (AchR) is 
used as negative control. For each cell line a single technical replicate was performed. 
 
To further demonstrate the involvement of BRD4 in JQ1 response, we performed silencing 
experiments using specific shRNAs targeting BRD4. After a first attempt using a constitutive 
silencing vector, we took advantage of a conditional silencing system where the expression of a 
specific shRNA is induced by the addition of Doxycycline  (Fellmann et al., 2013). All the 3 
independent shRNAs used caused more than 80% reduction in BRD4 expression that was 
maintained for up to 3 days (Fig.29). The decrease of mRNA detected was mirrored by the 
reduction of protein production, suggesting the efficacy of the shRNA used (Fig.30).  
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Fig. 29 shRNAs against BRD4 strongly reduce BRD4 mRNA production 
Expression analysis by RTqPCR to evaluate the level of BRD4 knock down after 0 (black), 1 (dark grey), 2 
(gray 50%) or 3 (light gray) days of shRNA induction through the administration of Doxycycline in RAJI. 3 
independent shRNA are used: shBRD4.602, shBRD4.1817, shBRD4.1838. The expression values are 
normalized on RPP0 levels. The mean and the standard deviations of 3 technical replicates are reported. 
 
Fig. 30 shRNAs against BRD4 strongly reduce BRD4 protein levels 
Analysis of BRD4 protein levels by Western Blot to evaluate the level of BRD4 downregulation after 0, 24 
or 48h of shRNA induction through Doxycycline administration in RAJI. 3 independent shRNA are used: 
shBRD4.602, shBRD4.1817, shBRD4.1838. Vinculin is used as loading control. In the lower panel the 
barplot shows the quantification of the Western Blot: BRD4 signal (black: 0h, dark gray: 24h, light gray: 
48h) is normalized on the Vinculin. Two technical replicates were performed and a representative western 
blot is shown. 
 
In order to verify if BRD4 silencing could phenocopy BETs inhibitor response, we analyzed the 
cellular and transcriptional effect mediated by shRNAs against BRD4. Expression analysis by 
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RTqPCR demonstrated that BRD4 silencing strongly downregulated genes sensitive to JQ1 
treatment, while the expression of genes insensitive to JQ1 remained constant up to 3 days after 
shRNA induction (Fig.31). 
 
Fig. 31 BRD4 silencing recapitulates JQ1 transcriptional effects 
Expression analysis by RTqPCR to evaluate the expression levels of genes sensitive or insensitive to JQ1 
after 0 (black), 1 (dark grey), 2 (gray 50%) or 3 (light gray) days of BRD4 silencing through the 
administration of Doxycycline in RAJI. 3 independent shRNA are used: shBRD4.602, shBRD4.1817, 
shBRD4.1838. The expression values are normalized on RPP0 levels. The mean and the standard deviations 
of 3 technical replicates are reported. 
 
Moreover, we performed cell cycle analysis to evaluate cytostatic effects following BRD4 
silencing (Fig.32). Doxycycline administration caused an increase from ~40% to ~60-70% in the 
G0/G1 population already after 24h and the percentage of arrested cells further increased after 48h 
of silencing (from 50% to ~80%).  
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Fig. 32 BRD4 silencing recapitulates the block in the cell cycle progression induced by JQ1 
Cell cycle analysis through BrdU incorporation (BrdU pulse: 20’) after shBRD4 induction through 
Doxycycline administration for 24 or 48h. 3 different shRNAs against BRD4 are used: shBRD4.602, 
shBRD4.1817, shBRD4.1838. DNA content is evaluated through PI staining. For each cell line a single 
technical replicate was performed. 
 
Whilst both BRD2 and BRD4 occupied the same genomic regions and JQ1 caused slight 
displacement of also BRD2 from the chromatin, we decided to use BRD4 as an approximation of 
the other BET members since the better quality of BRD4 ChIPseq data and the phenocopying 
effects of BRD4 silencing respect to JQ1 treatment. 
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Optimization of BET proteins Chromatin ImmunoPrecipitation 
Having realized the poor performance, in our hands, of published protocol for BRD4 ChIP, we set 
out to optimize the procedure in order to obtain high resolution ChIPseq maps. Indeed, BRD4 
ChIPseq experiments performed on RAJI using standard ChIP protocol with formaldehyde 
formaldehyde (FA) as fixative agent resulted in very low amount of immunopricipitated DNA. The 
quantity immunoprecipitated DNA strongly affected the quality of the ChIPseq library prepared, 
indeed ChIP signal was barely distinguishable from the background, with a consequent bad peak 
calling (only 884 BRD4 peaks were identified).  
The implementation of the fixation step, using a fixative able to create covalent bonds among 
proteins not directly bound to DNA (i.e. glutaraldehyde: GLUT), allowed us to immunoprecipitate 
BRD4 more effectively. Indeed, the good quality of BRD4 ChIP signal was evident both in 
ChIPqPCR (Fig.33) and in ChIPseq (Fig.34) analysis, since the enrichment signal after the 
standard fixation protocol (FA) was undistinguishable from the negative control (AchR) while the 
use of an alternative fixative agent (GLUT) allowed 30 fold enrichment over the background. 
Furthermore, we verified that the use of a stronger fixative step did not cause the 
immunoprecipitation of non specific protein performing BRD4 ChIP after the treatment with JQ1 
for 24h. Indeed we were still able to clearly detect BRD4 displacement from the chromatin 
(Fig.33-34).  
 
Fig. 33 Implementation of the fixation step increases the efficiency of BRD4 immunoprecipitation 
Analysis of BRD4 binding on IgH regulatory regions by ChIPqPCR for BRD4 on RAJI fixed for 10’ with 
formaldehyde or glutaraldehyde after treatment with DMSO (black) or 100 nM JQ1 (red) for 24h. 
Acetylcholine Receptor (AchR) is used as negative control. For RAJI fixed with FA the mean and the 
standard deviation of three technical replicates are reported; for RAJI fixed with GLUT a single replicate 
was performed. 
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Fig. 34 Implementation of the fixation step increases the efficiency of BRD4 immunoprecipitation 
Screenshot of BRD4 ChIPseq on RAJI fixed for 10’ with formaldehyde or glutaraldehyde after treatment 
with DMSO (black) or 100 nM JQ1 (red) for 24h. H3K27Ac, H3K4me3, H3K4me1 are used to identify 
open and active chromatin. Each ChIP sample was sequenced once. 
 
The improvement of signal to noise ratio was sufficient to properly proceed with further genome 
wide analyses, indeed we were able to identify 11915 different peaks. Furthermore, comparison of 
BRD4 peaks identified after standard or implemented fixation step showed that all the former 
peaks were include in the latter (Fig.35).  
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Fig. 35 The use of an alternative fixative enlarges the chromatin binding sites identified for BRD4 
Analysis of genome wide BRD4 binding using different fixation protocols: FA (formaldehyde: gray), GLUT 
(glutaraldehyde: red). In the Venn Diagram the overlapping area (gray+red) shows the number of BRD4 
common peaks, the red only and the gray only area represent the number of unique peaks identified after the 
fixation with GLUT or with FA, respectively. Each ChIP sample was sequenced once. 
 
Genome Wide mapping of BRD4  
To verify if the reduction in BRD4 binding mediated by JQ1 was limited to the genes analyzed by 
ChIPqPCR or instead if it was a common feature shared in a genome wide scale, we performed 
ChIPseq for BRD4 on cells treated with DMSO or JQ1 for 24h. As shown by the Venn Diagram in 
Fig.36, depicting the overlap between BRD4 ChIPseq in RAJI treated with DMSO or JQ1, the 
number of BRD4 peaks was strongly reduced after BETs inhibition, indeed only ¼ of peaks were 
still present in JQ1 sample (Fig.36). Furthermore, BRD4 peaks that were not displaced by JQ1 
were already present in the DMSO sample (Fig.36). Similar results were also obtained using the 
primary Eµ-Myc lymphoma cells where only half of BRD4 peaks was still present after the 
treatment with JQ1 (Fig.36). Whilst BETs inhibition strongly reduced BRD4 occupancy both in 
BL and in Eµ-Myc lymphoma cells, a difference in percentage of JQ1-resistent BRD4 peaks was 
evident.  
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Fig. 36 BETs inhibition efficiently impairs BRD4 genome wide binding 
Analysis of BRD4 chromatin binding in RAJI or Eµ-Myc lymphoma after treatment for 24h with DMSO 
(gray) or JQ1 (red). In the Venn diagram the overlapping regions (gray+red) represent the common BRD4 
peaks identified both in DMSO and in JQ1 samples. The gray only and the red only regions represent the 
number of BRD4 peaks identified uniquely in DMSO and JQ1 samples, respectively. Each ChIP sample was 
sequenced once. 
 
Nonetheless, the remaining BRD4 peaks in both RAJI and Eµ-Myc lymphoma cells were strongly 
less enriched than the DMSO counterpart, suggesting that JQ1 is exerting its activity on all BRD4 
peaks, since the vast majority of them was displaced while the residual peaks showed a marked 
reduction in signal intensity (Fig.37) 
 
Fig. 37 BETs inhibition causes a strong reduction in BRD4 intensity binding 
Quantification of reads associated to BRD4 peaks (rpm: reads per million) in RAJI or Eµ-Myc lymphomas 
after 24h treatment with DMSO (gray) or JQ1 (red). 
 
In order to have more insight into BRD4 chromatin binding, we performed a genomic distribution 
analysis of BRD4 peaks. As shown by the pie chart in Fig. 38, BRD4 peaks were equally 
distributed among promoter, intragenic and intergenic regions in RAJI. Moreover the allocation of 
BRD4 peaks was not strongly influenced by JQ1 treatment, since the percentage of peaks 
associated to promoter, intragenic and intergenic regions was comparable among DMSO and JQ1 
  Results 
 
 
66 
samples, suggesting the absence of a preferential displacement from a specific genomic location 
(Fig.38). Similar results were obtained also in Eµ-Myc lymphomas, where BRD4 occupied regions 
were equally assigned to genes or intergenic locations (Fig.38). 
  
Fig. 38 BETs inhibition does not affect BRD4 peaks distribution 
Analysis of genomic distribution (promoter: red, genebody: orange, intergenic: green) of BRD4 peaks after 
24h of treatment with DMSO (left) or JQ1 (right) in RAJI (upper panel) or Eµ-Myc lymphomas (lower 
panel). Each ChIP sample was sequenced once. 
 
Overall, the genome wide studies of BRD4 distribution in RAJI and Eµ-Myc cells showed that 
BRD4 was homogeneously disperse among promoter, intergenic and intragenic regions and that all 
BRD4 binding sites were sensitive to BETs inhibitor effects, since we noticed a reduction of 
number and intensity of the peaks regardless of the genomic localization. 
 
BETs inhibition affects Myc and E2F transcriptional programs 
Since BET proteins are involved in the regulation of transcription  (Jang et al., 2005; Yang et al., 
2005), we first investigated the genome wide transcriptional changes caused by JQ1. Using 
microarray assay, we were able to identify a small subset of genes affected by BETs inhibition; in 
particular we scored 1017 downregulated and 481 upregulated genes (JQ1-DEGs) in RAJI. 
RTqPCR analysis on genes selected from the downregulated or not-deregulated classes was used 
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to efficiently validate the genome wide assay, indeed we were able to confirm respectively the 
downregulation or the insensitivity to the JQ1 treatment using a different approach, obtaining a 
good correlation among the two techniques (R2=0.91) (Fig.39-40). Furthermore, the RTqPCR 
analysis suggested that genes responsive to BETs inhibition were downregulated in a dose-
dependent manner, while not responsive genes were unaffected even at high concentration of JQ1 
(Fig.39).  
 
Fig. 39 JQ1 responsive genes are downregulated in a dose-dependent manner, while JQ1 insensitive 
genes are not affected neither by high concentration of drug 
Expression analysis by RTqPCR in RAJI treated for 24h with DMSO or different concentration of JQ1 
(black: DMSO, red: 50 nM, orange: 100 nM, yellow: 500 nM) to validate downregulated or not deregulated 
genes obtained from Microarray assay. The expression levels are normalized on RPP0 and DMSO sample. 
The mean and the standard deviations of 3 technical replicates are reported. 
 
 
Fig. 40 RTqPCR validates genome wide expression data in RAJI 
Correlation plot to validate the genome wide expression data on RAJI treated for 24h with DMSO or JQ1. 
On the x axis the Log2 Fold Change obtained from RTqPCR is reported, while on the y axis the Log2 Fold 
Change obtained from Microarray assay is reported. 
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Similar results were obtained in Eµ-Myc lymphomas, where we investigated, through RNA 
sequencing (RNAseq), the transcriptional changes caused by BETs inhibition. Also in this system, 
we were able to identify a subset of JQ1 deregulated genes (608 downregulated and 840 
upregulated) that we validated by Nanostring® (Fig.41) and RTqPCR (Fig.42) assays.  
 
Fig. 41 Nanostring assay validates genome wide expression data in Eµ-Myc lymphomas 
Correlation plot to validate the genome wide expression data on Eµ-Myc lymphomas (9644, 27805 and 
28514) treated for 24h with DMSO or JQ1. On the x axis the Log2 Fold Change obtained from RNAseq is 
reported, while on the y axis the Log2 Fold Change obtained from Nanostring assay is reported. 
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Fig. 42 RTqPCR validates genome wide expression data in Eµ-Myc lymphomas 
Expression analysis by RTqPCR to validate downregulated or not deregulated genes identified through 
RNAseq assay in Eµ-Myc lymphomas (9644, 27805 and 28514) treated with DMSO (black) or 50 nM of 
JQ1 (red) for 24h. The expression values are normalized on RPP0 and DMSO sample. The mean and the 
standard deviations of 3 technical replicates are reported. 
 
We functionally annotate JQ1-DEGs by performing Gene Set Enrichment Analysis (GSEA)  
(Subramanian et al., 2005) using different collections from Molecular Signature Database 
(MSigDB) (Subramanian et al., 2005) as gene sets of reference. While upregulated genes in RAJI 
did not show robust enrichment for any gene set, analysis of downregulated genes using MSigDB 
collection for Gene Ontology (GO) terms (C5) showed strong enrichment for genes involved in the 
cell cycle control and DNA replication or G2/M checkpoint, as expected since the block in G1 
after JQ1 treatment (Fig.43). 
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Fig. 43 BETs inhibition deregulates genes involved in cell cycle control 
Gene Ontology analysis using expression genome wide data, obtained through microarray assay in RAJI 
treated with DMSO or JQ1 for 24h. The Gone Ontology C5 collection from MSigDB is used. In the upper 
panel representative enrichment plots are reported. In the lower panel, the top10 GO terms are reported. 
Normalized Enrichment Score (NES) and False Discovery Rate (FDR) values are reported. 
 
GO_term SIZE ES NES FDR	q-val
CELL_CYCLE_PROCESS 174 -0.7248 -2.74772 0
CELL_CYCLE_PHASE 156 -0.71301 -2.6616 0
MITOTIC_CELL_CYCLE 143 -0.71132 -2.62671 0
DNA_METABOLIC_PROCESS 223 -0.65015 -2.55767 0
M_PHASE 101 -0.71945 -2.52673 0
CHROMOSOME 113 -0.69598 -2.50958 0
CELL_CYCLE_GO_0007049 286 -0.63248 -2.47855 0
MITOSIS 75 -0.72658 -2.47655 0
CHROMOSOMAL_PART 88 -0.71137 -2.46899 0
M_PHASE_OF_MITOTIC_CELL_CYCLE 78 -0.72229 -2.45903 0
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In order to identify the key transcription factors associated to BETs inhibition response, we further 
characterized the JQ1-DEGs performing GSEA using as gene set of reference already published 
Myc ChIPseq in RAJI cells and the collections for Oncogenic Signature (C6) from MSigDB. As 
shown in Fig. 44-45, genes downregulated after JQ1 treatment were enriched for genes bound by 
Myc (Fig.44) and positively regulated by E2F1 (Fig.45). 
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Fig. 44 JQ1 sensitive genes in RAJI were enriched for Myc targets 
Gene Set Enrichment Analysis using expression genome wide data, obtained through microarray assay, in 
RAJI treated with DMSO or JQ1 for 24h using already published Myc ChIPseq on RAJI  (Seitz et al., 2011). 
 
Fig. 45 JQ1 sensitive genes in RAJI were enriched for E2F1 regulated genes 
Gene Set Enrichment Analysis using expression genome wide data, obtained through microarray assay, in 
RAJI treated with DMSO or JQ1 for 24h using Oncogenic Signature Collection (C6 collection) from 
MSigDB. 
 
The enrichment in the downregulated genes for Myc targets or for genes that contain the 
recognition elements for Myc-Max binding was also confirmed in the Eµ-Myc system, performing 
GSEA with Transcription Factor motif or Oncogenic Signature collections (C3 and C6, 
respectively) (Fig.46).  
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Fig. 46 JQ1 sensitive genes in Eµ-Myc lymphomas were enriched for Myc bound and regulated genes 
Gene Set Enrichment Analysis using genome wide expression data, obtained through RNAseq, in Eµ-Myc 
lymphomas treated with DMSO or JQ1 for 24h. Transcription Factor motif and Oncogenic Signature (C3 
and C6, respectively) collections from MSigDB are used as gene set of reference. 
 
Altogether, the genome wide expression analysis on RAJI and Eµ-Myc lymphomas pointed out 
that genes involved in the cell cycle control and Myc and E2F1 targets were preferentially 
downregulated after treatment with BETs inhibitor. Since the downregulation of the same classes 
of genes was already reported in MM cells  (Delmore et al., 2011), we tested if there was similarity 
between the altered transcriptional programs in different contexts. To verify this possibility, we 
performed GSEA using as gene set of reference the lists of deregulated genes obtained from 
Delmore et al., (2011). As shown in Fig.47, genes identified as downregulated in MM cells in  
Delmore et al., (2011) were enriched for genes downregulated in RAJI, while genes upregulated in 
MM were enriched for upregulated transcripts in RAJI, suggesting that BRD4 inhibition in 
different lines leads to the alteration of similar pathways. 
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Fig. 47 BETs inhibition altered the similar transcriptional program in different contexts 
Gene Set Enrichment Analysis using genome wide expression data on RAJI treated with DMSO or JQ1 for 
24h using as gene set of reference the list of deregulated genes in MM.1S cells treated with JQ1already 
published  (Delmore et al., 2011). 
 
Thus, regardless the alteration of Myc levels, the final transcriptional outcome, in response to 
BRD4 inhibition, is comparable in different cellular contexts and it mainly affects Myc/E2F1 
targets thereby accounting for the strong cytostatic effect exerted by JQ1 in these cell lines. 
 
Myc and E2F1 genomic occupancy is not altered by BETs inhibition 
Since Myc and E2F1 target genes were downregulated following JQ1 treatment, we asked whether 
the treatment with BETs inhibitors would affect Myc or E2F1 chromatin distribution.  
As a first step in the analysis, we investigated the genomic distribution of the two transcription 
factors in RAJI cells and asked whether their localization would be altered after BET inhibition. 
As expected, in the control samples, Myc was equally distributed among either promoters, 
intergenic and intragenic regions (Fig.48), while E2F1 was preferentially localized in the 
proximity of promoters (Fig.48). Myc and E2F1 binding was not influenced by JQ1 treatment, 
since the total number of peaks and their localization were comparable among the two conditions, 
as displayed in the pie chart for genomic distribution and Venn diagram showing the overlap 
between peaks identified in the treated versus untreated sample (Fig.48-49).  
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Fig. 48 BETs inhibition does not change genomic localization of Myc or E2F1 binding 
Analysis of genomic distribution (promoter: red, genebody: orange, intergenic: green) of Myc (left) or E2F1 
(right) ChIPseq peaks in RAJI treated with DMSO (upper panel) or JQ1 (lower panel) for 24h. Each ChIP 
sample was sequenced once. 
 
 
Fig. 49 BETs inhibition does not reduce global Myc and E2F1 binding in RAJI 
Analysis of BRD4 chromatin binding in RAJI or Eµ-Myc lymphoma after treatment for 24h with DMSO 
(gray) or JQ1 (red). In the Venn diagram the overlapping regions (gray+red) represent the common BRD4 
peaks identified both in DMSO and in JQ1 samples. The gray only and the red only regions represent the 
number of BRD4 peaks identified uniquely in DMSO and JQ1 sample, respectively. Each ChIP sample was 
sequenced once. 
 
In order to verify if BETs inhibition affects the intensity of Myc and E2F1 binding, we further 
analyzed the ChIPseq data, quantifying the reads localized in the proximity of the TSS of Myc or 
E2F1 targets. The intensity of Myc or E2F1 promoter peaks was not reduced by BETs inhibition, 
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on the contrary JQ1 treated samples showed a slight increase in the read density around the TSS 
(Fig.50).  
 
Fig. 50 BETs inhibition does not impair the TSS binding of Myc or E2F1 in RAJI 
Reads distribution around the TSSs for Myc (upper panels) or E2F1 (lower panels) ChIPseq in RAJI after 
DMSO (black line) or JQ1 (red line) treatment for 24h. The input is used to set the background levels. The 
quantification of the reads distribution is reported in the boxplot on the right. Paired t-test is used to evaluate 
statistical significant differences. Each ChIP sample was sequenced once. 
 
Therefore, the downregulation of Myc and E2F1 dependent genes observed after JQ1 treatment 
could not be explained by the displacement of the two TFs from the promoter of their target genes. 
To gain further confirmation of the lack of alteration of TF binding after BETs inhibition, we 
performed Myc ChIPseq in Eµ-Myc lymphomas treated with DMSO or JQ1 for 24h. As shown in 
figures 51-52, neither the total number of Myc peaks (Fig.51) nor its binding intensity on the TSS 
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(Fig.52) were reduced by JQ1 treatment, on the contrary we noticed a slight increase both in the 
number of peaks and in the intensity of Myc TSS binding after BETs inhibition. 
 
Fig. 51 BETs inhibition does not alter global Myc chromatin occupancy in Eµ-Myc lymphomas 
Analysis of Myc chromatin binding in Eµ-Myc lymphomas treated with mock (DMSO: gray) or JQ1 (red). 
The overlap region (gray+red) in the Venn Diagram represents the number of common peaks between the 
two conditions. The only gray and only red parts represent the unique peaks in DMSO and JQ1 sample, 
respectively. Myc ChIPseq was performed in 3 independent Eµ-Myc lymphomas and the merge of the three 
sequencing was used for the analysis. 
 
Fig. 52 BETs inhibition does not impair the TSS binding of Myc in Eµ-Myc lymphomas 
Analysis of Myc binding on the TSS of its target through quantification of reads distribution around the 
TSSs for Myc ChIPseq in Eµ-Myc lymphomas after DMSO (black) or JQ1 (red) treatment for 24h. In the 
left panel, it is shown the TSS profile of Myc ChIPseq. The input is used to set the background level. In the 
right panel, the boxplot shows the quantification of reads distribution. Paired t-test is used to evaluate 
statistical significant differences. Myc ChIPseq was performed in 3 independent Eµ-Myc lymphomas and 
the merge of the three sequencing was used for the analysis. 
 
In order to further verify if the response to BETs inhibitor was independent on the levels of TFs, 
we tested the JQ1 effects in cells where either Myc or E2F levels and activity could be raised by 
ectopic overexpression. To modulate the activation of Myc, we took advantage of the Myc-ER 
system, where Myc is fused to a modified form of the Estrogen Receptor (ER) which is responsive 
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to 4-Hydroxytamoxyfen (OHT). Once OHT is added to the cell culture, Myc-ER fusion protein is 
shuttled into the nucleus and free to transcribe its target genes. As a first step, we evaluated cell 
growth of two independent Myc-ER cell lines cultured in the presence of JQ1. As shown in Fig.53, 
both control and OHT treated cells were sensitive to BETs inhibition: not only OHT addition (i.e. 
ectopic Myc activation) did not rescue the cell growth arrest, but cells in which Myc-ER was 
activated seemed slightly more sensitive to BETs inhibition, in line with previous publication 
where based on a genome wide screen in Myc overexpressing cells, BRD4 was identified as a gene 
synthetic lethal with Myc  (Toyoshima et al., 2012).  
 
Fig. 53 Enhanced Myc activity is not sufficient to compensate growth arrest caused by BETs inhibition  
Cell growth assay using CellTiterGlo on primary Murine Embrionic Fibroblast (MEF) infected with 
pBabePuro-MycER and treated with OHT (right panel), to induce Myc activation, or EtOH (left panel), as 
control, in combination with different concentration of JQ1 (black: DMSO, red: 100 nM, orange: 250 nM) 
for up to 4 days. Two independent MEFs preparations (N3 and N7) are used. The mean and the standard 
deviations of 3 technical replicates are reported. 
 
As we already verified for cancer cell lines, also in this context BETs inhibition main effect was a 
block in the cell cycle progression with a consistent decrease in the percentage of cells in S phase, 
as demonstrated by BrdU incorporation and labeling after 48h of JQ1 treatment in combination 
with Myc activation (Fig.54). 
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Fig. 54 Myc increased activity is not sufficient to prevent block in the cell cycle progression induced by 
BETs inhibition 
Cell cycle analysis through BrdU incorporation (pulse 20’) on primary MEFs infected with pBabePuro-
MycER and treated with OHT, to induce Myc activation, or EtOH, as control, in combination with different 
concentration of JQ1 (0-100-250 nM) for 48h. In the lower panel a barplot depicting the % of BrdU positive 
cells is reported. Two independent MEFs preparations (N3 and N7) are used. 
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From this phenotypical analysis, we collected evidences that high Myc activity, rather than 
rescuing, is actually sensitizing cells to BET inhibition. In order to verify if ectopic activation of 
Myc could at least prevent the downregulation of Myc target genes after BETs inhibition, we 
performed RTqPCR on MEFs infected with pBabePuro-Myc-ER after JQ1 treatment and/or OHT 
administration (Fig.55). The analysis of the expression levels on selected Myc targets clearly 
demonstrated that BETs inhibition caused a reduction in their expression levels and that Myc 
enhanced activity was not sufficient to prevent this transcriptional response, suggesting that BRD4 
affects transcription of these genes at a level that is downstream Myc binding to its targets. 
 
Fig. 55 Myc overexpression is not sufficient to prevent JQ1transcriptional effects on Myc targets 
Expression analysis by RTqPCR on Myc target on primary Murine Embrionic Fibroblast (MEF) infected 
with pBabePuro-MycER and treated with different concentration of JQ1 (black: DMSO, red: 100 nM, 
orange: 250 nM) in combination with EtOH (mock) or OHT treatment to induce Myc activation. Two 
independent MEFs preparations (N3 and N7) are used. The expression values are normalized on RPP0 
expression. The mean and the standard deviations of 3 technical replicates are reported. 
 
The previously described GSEA on RAJI highlighted the alteration of both Myc and E2F 
transcriptional program (Fig.44-45). Therefore we decided to test if E2F1 overexpression could be 
sufficient to bypass BET inhibition. To verify this hypothesis, we infected RAJI cells with a 
constitutive vector overexpressing E2F1 and we analyzed the effect of JQ1 treatment in terms of 
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transcriptional response of some E2F1 target genes. As shown in Fig.56, the downregulation of 
E2F1 targets caused by BET inhibition was not bypassed by the ectopic expression of the 
transgene.  
 
Fig. 56 E2F1 overexpression is not sufficient to prevent JQ1 transcriptional effects on E2F1 targets 
Expression analysis by RTqPCR on E2F1 targets on RAJI infected with pBabePuro-EV or pBabePuro-
E2F1-HA and treated for 24h with DMSO (black) or 100 nM JQ1 (red). The expression values are 
normalized to RPP0 expression. The mean and the standard deviations of 3 technical replicates are reported. 
 
In order to rule out the possibility of a cooperation between Myc and E2F1 and the need of the 
double overexpression to overcome BET inhibition, we performed E2F1 overexpression 
experiments in MEFs where Myc-ER transgene was knocked in (KI) under the control of the 
Rosa26 promoter. As it is shown in Fig.57-58, even though we were able to properly 
overexpressed E2F1, the cell growth response to JQ1 treatment was not rescued by the 
combination of Myc activation and E2F1 overexpression. 
 
Fig. 57 E2F1 is efficiently overexpressed in MEFs 
Analysis of E2F1 protein level by Western Blot on primary MEFs Wilde Type (WT) or MycER Knock-in 
(KI) not infected or infected with pBabePuro-EV or pBabePuro-E2F1-HA. A single replicate was 
performed. 
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Fig. 58 E2F1 overexpression and Myc activation are not sufficient to overcome BETs inhibition 
impairment of cell growth 
Cell viability assay on primary MEFs Wilde Type (WT) or MycER knock in (KI) infected with pBabePuro-
EV (upper panel) or pBabePuro-E2F1-HA (lower panel) and treated for up to 4 days with different 
concentration of JQ1 (black: DMSO, orange: 100 nM, yellow: 250 nM) and with EtOH (solid lines) or OHT 
(dashed lines), to induce Myc activation. The mean and the standard deviations of 3 technical replicates are 
reported.  
 
 
Characteristics of JQ1 responsive genes 
Since BETs inhibition alters the expression of a defined set of genes, shared by different cell lines, 
we wondered whether we could identify features that specifically characterized these JQ1 
responsive genes. With this idea in mind, we performed an integrated analysis of the transcriptome 
and the chromatin profiles obtained by the ChIPseq. As a first level of investigation, we analyzed 
if JQ1 responsive genes show differences in their expression levels in comparison to the not 
deregulated ones. Indeed, quantifying the expression in the DMSO treated samples, we observed 
that in RAJI cells the class of downregulated genes was characterized by a significant higher level 
of expression respect to not-deregulated genes (Fig.59).  
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Fig. 59 JQ1 sensitive genes are expressed at high levels 
Expression quantification through Microarray assay in RAJI for NO-DEG, DOWN or UP regulated genes 
identified through Microarray analysis in RAJI after treatment with JQ1. Unpaired t test (two tails) is used. * 
pvalue=0.0259; **** pvalue<0.0001. 
 
In order to verify if this higher expression level in the downregulated genes could be associated to 
the presence of specific chromatin features, we investigated the chromatin occupancy of different 
transcription factors or histone marks (Fig.60) in RAJI. Focusing our attention on downregulated 
genes, we noticed that the vast majority of the TSS in the DMSO sample was simultaneously 
bound by BRD4 and by Myc and E2F1, as predicted by the GSEA analysis. On the contrary, only 
a small fraction of not deregulated genes showed the presence of BRD4 and the transcription 
factors Myc and E2F1 (Fig.60) on their TSS. Furthermore, it is worth to notice that, regardless of 
the group identity (downregulated or not-deregulated), the genes characterized by the presence of 
RNA PolII and by the histone marks for active chromatin (H3K27Ac, H3K4me1, H3K4me3) were 
also bound by BRD4, that, as expected, is strongly depleted after BETs inhibition. This evidence 
suggested that, even though BETs inhibition ultimately affects the expression of a limited number 
of genes, BRD4 is bound to all the promoters of genes actively transcribed (Fig.60).  
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Fig. 60 JQ1 sensitive genes are preferentially bound by BRD4, TFs (Myc and E2F1) and RNA PolII in 
RAJI 
Digital heatmap showing the distribution of BRD4, Med1, TFs (Myc and/or E2F1), RNA PolII and histone 
marks (H3K27AC, H3K4me1 and H3K4me3) in no-deregulated or downregulated genes in RAJI after the 
treatment for 24h with DMSO or JQ1. Each ChIP sample was sequenced once. 
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These results were also confirmed using available ChIPseq data for MM.1S  (Delmore et al., 2011) 
and for a Diffuse Large B Cell Lymphoma cell line (OC-LY1) (Chapuy et al., 2013) after BETs 
inhibition. In both cell lines, regions marked with histone modifications for open and active 
chromatin were also bound by BRD4, furthermore there was a strong association between BRD4 
binding and RNA PolII/Myc. Moreover, also in these cellular models, downregulated genes were 
highly enriched for targets of Myc, in contrast to not-deregulated genes (Fig.61-62).  
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Fig. 61 JQ1 sensitive genes are preferentially bound by BRD4, E2F1 and RNA PolII in MM.1S 
Digital Heatmap showing the distribution of BRD4, Med1, RNA PolII, Myc, CDK9 and histone marks 
(H3K27Ac and H3K4me3) in no-deregulated or downregulated genes after JQ1 treatment in MM.1S. 
Expression data and ChIPseq data used to perform this analysis were public available  (Delmore et al., 2011; 
Lovén et al., 2013) . 
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Fig. 62 JQ1 sensitive genes are preferentially bound by BRD4, E2F1 and RNA PolII in OC-LY1 
Digital Heatmap showing the distribution of BRD4, RNA PolII, E2F1 and histone marks (H3K27AC, and 
H3K4me3) in no-deregulated or downregulated genes in OC-LY1 after the treatment for 24h with DMSO or 
JQ1. Expression data and ChIPseq data used for this analysis were obtained from  (Chapuy et al., 2013). 
 
In order to extend these observations, we verified also in the Eµ-Myc lymphomas the chromatin 
landscape for downregulated or not-regulated genes after BETs inhibition. Also in Eµ-Myc 
lymphomas, we still observed the strong correlation between TSS marked with transcription 
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factors/RNA PolII/active histone marks and BRD4, but we were not able to discriminate between 
responding versus not responding genes based on the binding pattern, since also the latter class of 
genes was strongly enriched for Myc/RNA PolII bound genes (Fig.63). This difference could be 
due to the biology of Eµ-Myc lymphomas: in this cellular system, Myc is expressed at very high 
levels and a phenomenon called “invasion” occurs  (Lin et al., 2012; Sabò et al., 2014). Briefly, 
when Myc is expressed at physiological and low levels, it binds only few targets with the 
canonical E-box sequences in their promoter; once Myc is overexpressed it will bind also not 
canonical E-boxes, both at the promoter and at the enhancer regions, invading all the regulatory 
regions. This phenomenon will explain why we were not able to discriminate among JQ1 sensitive 
and insensitive genes based on Myc binding.  
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Fig. 63 JQ1 responsive genes are not distinguishable from not deregulated ones based on chromatin 
occupancy in Eµ-Myc lymphomas 
Digital Heatmap showing the distribution of BRD4 (DMSO or JQ1 sample) and Myc, RNA PolII and 
H3K27Ac in 3 different Eµ-Myc lymphomas.  
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Since these heatmaps are digital representations of the occupancy of a particular region, we 
decided to analyze also the binding intensity of each factor on the TSS of the genes belonging to 
the different classes (Fig.64). From the analysis in RAJI of the reads distribution around the TSS, 
we noticed a much higher intensity binding of BRD4, Myc & E2F1 and RNA PolII in 
downregulated genes respect to not-deregulated ones (Fig.64). These data are in line with the 
results obtained in MM.1S cell line: in fact, also in this cellular system the downregulated genes 
were characterized by a very high binding of BRD4, Myc and RNA PolII (Fig.64).  
This analysis suggested that the promoters of downregulated genes are (over)loaded with BRD4 
and other TFs that, attracting more RNA PolII, may ensure a higher expression level in basal 
conditions.  
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Fig. 64 JQ1 sensitive genes are characterized by high intensity binding of BRD4, TFs and RNA PolII 
on the TSSs 
Reads distribution around the TSSs in no-deregulated or downregulated genes in RAJI (upper panels) or 
MM.1S (lower panels) after DMSO (black line) or JQ1 (red line) treatment. For RAJI BRD4, Myc, E2F1 
and RNA PolII ChIPseq are analyzed. Each ChIP sample was sequenced once. For MM.1S BRD4, Myc and 
RNA PolII ChIPseq already published are used  (Delmore et al., 2011; Lovén et al., 2013).  
 
 
BRD4 inhibition causes alteration of RNA PolII dynamics 
Since the ChIPseq data clearly showed that the deregulation of Myc and E2F1 targets did not 
correspond to a reduced binding of these TFs on the promoter of their targets, and the 
overexpression experiments suggested that the BETs inhibitors act downstream the binding of a 
TF on the promoter of its targets, we wondered whether gene downregulation caused by BETs 
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inhibition was actually linked to alterations of RNA PolII activity. To address this question, we 
performed ChIPseq on RNA PolII in RAJI treated with JQ1. Analysis of the RNA PolII peaks 
distribution (Fig.65) showed that the binding sites were mainly localized in the genebody (around 
50%) and on the promoter (30%), while a minority of peaks were localized in the intergenic 
regions, as expected. Moreover, BETs inhibition did not change the global binding of RNA PolII 
to the chromatin (Fig.65-66), suggesting no massive alteration of RNA PolII occupancy after 
BRD4 inhibition.  
 
Fig. 65 BETs inhibition does not alter the global genomic distribution of RNA PolII in RAJI 
Analysis of genomic distribution in Promoters (red), Genebody (orange) and Intergenic (green) regions of 
RNA PolII peaks in RAJI treated with DMSO (left) or 100 nM of JQ1 (right) for 24h. Each ChIP sample 
was sequenced once. 
 
Fig. 66 BETs inhibition does not reduce the number of RNA PolII binding sites in RAJI 
Analysis of RNA PolII chromatin binding in RAJI treated with mock (DMSO: gray) or JQ1 (red) for 24h. 
The overlap region (gray+red) in the Venn Diagram represents the number of common peaks between the 
two conditions. The only gray and only red parts represent the unique peaks in DMSO and JQ1 samples, 
respectively. Each ChIP sample was sequenced once. 
 
Nonetheless, the inhibition of BRD4 might affect RNA PolII processivity. To test this hypothesis, 
we evaluated the Stalling Index (SI). This value takes into account the signal of RNA PolII on the 
promoter and on the genebody of transcribed genes (Fig.67): usually, an high SI value is 
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associated to high levels of RNA PolII on promoter (stalled PolII) and/or low level of traveling 
RNA PolII on the genebody (related to the block in the elongation step). From this analysis, we 
noticed that the SI associated to RAJI treated with JQ1 was higher than the control (DMSO) 
sample, regardless of the class of genes analyzed (Fig.67). In particular, the compromised 
elongation step was evident in JQ1 downregulated genes, in which the RNA PolII signal in the 
genebody was strongly reduced while the occupancy on the promoter was not affected, as shown 
by the SI plot and by the RNA PolII profile and reads quantification in Fig.67. On the contrary, the 
not-deregulated (Fig.67) and upregulated (Fig.67) genes were characterized by a higher RNA PolII 
signal on the promoter without massive changes on the genebody. 
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Fig. 67 BETs inhibition strongly affects RNA PolII dynamics in RAJI 
Evaluation of the RNA PolII dynamics in RAJI after treatment with DMSO (black) or JQ1 (red) for 24h. In 
the upper panel a schematic representation of Stalling Index evaluation was reported. (A) Stalling Index is 
calculated for not-deregulated, downregulated and upregulated genes. The left panel summarizes the global 
SI, the middle panel shows the quantification of RNA PolII on the TSS, while the right panel shows the 
quantification of RNA PolII reads on the GeneBody (GB). (B) RNA PolII profiles along the gene. The 
dashed line represents the background (input) signal. (C) Boxplot to quantify RNA PolII reads on the TSS, 
on the GB and on the TES. Pair t-test is calculated for each DMSO-JQ1 pair. Each ChIP sample was 
sequenced once. 
 
In order to verify if the stalling of the RNA PolII on downregulated genes would lead to a 
reduction in the transcription rate, we performed 4-thioUridine (4-sU) labeling, followed by 
RTqPCR. This technique, indeed, allows the specific labeling of the newly synthesized mRNA. As 
shown in Fig.68, downregulated genes showed a 60% reduction in the production of new 
transcripts after the treatment with JQ1, while no differences were evident in the not-deregulated 
genes.  
 
Fig. 68 JQ1 treatment affects the mRNA production of downregulated genes 
Quantification by RTqPCR of ongoing transcription in genes not deregulated or downregulated by 24h JQ1 
treatment in RAJI. The newly synthesized RNA is labeled with a 30’ pulse of 4-sU. The total number of 
copies of labeled RNA in the JQ1 sample over the DMSO is reported. In order to discriminate the immature 
from the spliced mRNA, primers are designed at the intro-exon boundary. One technical replicate per two 
biological replicates were performed and a representative plot is shown. 
 
The analysis on RNA PolII dynamics and the 4-sU labeling results suggested that BRD4 inhibition 
affected the synthesis of downregulated genes by selectively compromising their transcriptional 
  Results 
 
 
96 
elongation. On the contrary, the transcription of not-deregulated genes was not altered, probably 
because the initial reduction on the elongating RNA PolII was immediately compensated by a 
higher recruitment of RNA PolII on the promoter, as it is suggested by the higher ChIPseq signal 
of promoter associated polymerase.  
In order to verify if the stalling of the RNA PolII is an effect shared also by other cell lines, we 
performed the SI evaluation on RNA PolII ChIPseq in MM.1S (Fig.69) or OC-LY1 (Fig.70) cells 
using published datasets  (Chapuy et al., 2013; Lovén et al., 2013). Also in these cell lines, JQ1 
treatment strongly affected the RNA PolII rate. In particular, downregulated genes were 
characterized by a reduction of RNA PolII signal on the genebody, without any change at the 
promoter level (Fig.69-70); while not-deregulated (Fig.69-70) and upregulated genes (Fig.69-70) 
were marked with a higher RNA PolII density on their promoter.  
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Fig. 69 BETs inhibition strongly affects RNA PolII dynamics in MM.1S 
Evaluation of the RNA PolII dynamics in MM.1S after treatment with DMSO (black) or JQ1 (red). (A) 
Stalling Index is calculated for not-deregulated, downregulated and upregulated genes. The left panel 
summarizes the global SI, the middle panel shows the quantification of RNA PolII on the TSS, while the 
right panel shows the quantification of RNA PolII reads on the GeneBody (GB). (B) RNA PolII profiles 
along the gene for not-deregulated, downregulated and upregulated genes. The dashed line represents the 
background (input) signal. (C) Boxplot to quantify RNA PolII reads on the TSS, on the GB and on the TES. 
Pair t-test is calculated for each DMSO-JQ1 pair. For this analysis already published data are used  (Delmore 
et al., 2011; Lovén et al., 2013)  
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Fig. 70 BETs inhibition strongly affects RNA PolII dynamics in OC-LY1 
Evaluation of the RNA PolII dynamics in OC-LY1 after treatment with DMSO (black) or JQ1 (red). (A) 
Stalling Index is calculated for not-deregulated, downregulated and upregulated genes. The left panel 
summarized the global SI, the middle panel shows the quantification of RNA PolII on the TSS, while the 
right panel shows the quantification of RNA PolII reads on the GeneBody (GB). (B) RNA PolII profiles 
along the gene for not-deregulated, downregulated and upregulated genes. The dashed line represents the 
background (input) signal. For this analysis already published data are used  (Chapuy et al., 2013)  
 
Further indications of alteration of RNA PolII dynamics and processivity derived from analysis of 
its phosphorylation status. After the recruitment on the promoter, RNA PolII needs to be 
phosphorylated on Serine5 (Ser5) and Serine 2 (Ser2) of its CTD in order to be active and to start 
gene transcription  (Kwak and Lis, 2013). In particular, the phosphorylation on Ser5 of RNA PolII 
CTD is mediated by CDK7 during the initiation step of the transcription process and it is 
characteristic of primed and promoter-paused RNA PolII. Instead, the modification of Ser2 is 
mediated by CDK9, the kinase of the positive elongation factor pTEFb, and it is necessary for the 
transition from the initiation to the elongation step. In order to verify if the treatment with JQ1 
caused global alteration of the phosphorylation status, we checked by Western Blot the level of 
phosphorylated RNA PolII with specific antibodies, previously tested, and that recognize 
exclusively the RNA PolIIS5p or RNA PolIIS2p forms. After the treatment with JQ1, neither RNA 
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PolIIS5p nor RNA PolIIS2p levels were decreased (Fig.71), suggesting the absence of a global 
alteration in RNA PolII phosphorylation status.  
 
Fig. 71 BETs inhibition does not cause a global reduction in RNA PolII phosphorylated forms 
Analysis of RNA PolIIS2p and RNA PolIIS5p levels by Western Blot in RAJI treated with different 
concentration of JQ1 (0-50-100-500 nM) for 6 or 24h. Total RNA PolII was used to monitor eventual 
alteration in the levels of total RNA PolII. Ponceau is used as loading control. Two technical replicates were 
performed and a representative blot is shown. In the lower panels, the barplots show the quantification of the 
phosphor RNA PolII over the total. 
 
In order to assess differences in RNA PolII phosphorylation that could be characteristic and 
restricted to JQ1 responsive genes, we performed ChIPseq on phosphorylated RNA PolII forms 
(RNA PolIIS2p and RNA PolIIS5p) and we analyzed their distribution along the genes of the 
different classes of genes. This analysis showed that the distribution of RNA PolIIS2p was 
strongly affected by BETs inhibition, in particular the JQ1 responsive genes were characterized by 
a strong decrease in the levels of RNA PolIIS2p both in the genebody and on the Transcriptional 
End Site (TES), as shown both in the gene profile and in the quantification of the intensity of the 
phosphorylated RNA PolII respect to the total form (Fig.72), supporting the hypothesis that BET 
inhibition led to a decrease in the elongating RNA PolII in this class of genes. On the contrary, 
both upregulated and not affected genes showed a global increase in the RNA PolIIS2 
phosphorylated forms (Fig.72). While for the upregulated genes this result was expected, since 
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they responded to BET inhibition with an increase in transcription, the results for the not 
deregulated genes was a further support to our hypothesis of a compensatory mechanism that can 
counterbalance the effect of JQ1 by recruiting more RNA PolII on the TSS of the genes and thus 
leading to an increase in the elongating RNA PolII.  
 
Fig. 72 BETs inhibition strongly affects elongating RNA PolII (S2p) 
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Analysis of RNA PolIIS2p in not deregulated (NO-DEG), downregulated (DEG-DOWN) or upregulated 
(DEG-UP) genes after 24h JQ1 treatment in RAJI. In the upper panel the analysis of RNA PolIIS2p 
distribution along the genes in DMSO (black) or JQ1 (red) is reported. The dashed line represents the 
background level (input). 
In the lower panel, the amount of phosphorylated Ser2 RNA PolII over the total form in the Genebody (GB) 
or Transcription End Site (TES) is evaluated. Pair t-test is performed to evaluate statistical significant 
differences among DMSO (gray) and JQ1 (red) samples. Each ChIPseq sample was sequenced once. 
 
Moreover, from the analysis of RNA PolIIS5 phosphorylated form, we noticed that downregulated 
genes showed a strong decrease in the RNA PolIIS5p along the genebody, with no significant 
changes at the TSS (Fig. 73), supporting the idea that less initiating RNA PolII is able to escape 
from the TSS in order to complete the transcription. The not deregulated and upregulated genes 
showed a clear increase in the Ser5 phosphorylated form both at the TSS and on the genebody 
(Fig.73). Furthermore, the increased Ser5p/Tot ratio (Fig.57) both in not-deregulated and 
upregulated genes denoted an enhancement of the phosphorylation mediated by CDK7 after BETs 
inhibition, suggesting that the compensatory effect may be mediated also by an active recruitment 
and priming of RNA PolII, rather than a simple release from the TSS of RNA PolII molecules 
already present. 
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Fig. 73 BETs inhibition induces phosphorylation of RNA PolII on the Serine 5 
Analysis of RNA PolIIS5p in not deregulated (NO-DEG), downregulated (DEG-DOWN) or upregulated 
(DEG-UP) genes after 24h JQ1 treatment in RAJI. In the upper panel the analysis of RNA PolIIS2p 
distribution along the genes in DMSO (black) or JQ1 (red) is reported. The dashed line represents the 
background level (input). 
In the lower panel, the amount of phosphorylated Ser5 RNA PolII over the total form in the Genebody (GB) 
or Transcription End Site (TES) is evaluated. Pair t-test is performed to evaluate statistical significant 
differences among DMSO (gray) and JQ1 (red) samples. Each ChIPseq sample was sequenced once. 
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These observations suggested that BRD4 regulates RNA PolII elongation, while this is a general 
effect that will likely concern any transcribed gene, the decrease in the transcription rate will 
specifically affect a subset of expressed genes which will be unable to compensate the drop in 
elongation rate with the increase in RNA PolII recruitment.  
 
Cdk9 inhibition preferentially downregulates JQ1 sensitive genes 
Several experimental evidences suggest that BRD4 is a positive co-factor in the regulation of gene 
transcription, since it is necessary for the recruitment of Positive Elongation Factor (pTEFb 
composed by CDK9 and Cyc T1) on the promoter of target genes, allowing the phosphorylation on 
Serine 2 of RNA PolII  (Jang et al., 2005; Yang et al., 2005). Since our data showed that JQ1 
responsive genes are particularly sensitive to alteration in RNA PolII elongation, we wondered 
whether this class of genes would be similarly sensitive to other inhibitors of RNA PolII 
elongation. To answer to this question, we analyzed the transcriptional response after inhibition of 
CDK9, using two well-known CDK9 inhibitors (e.g. DRB and PHA-767491) on both JQ1 
responsive and not responsive genes. As shown in Fig.74, genes sensitive to BET inhibition were 
preferentially downregulated by CDK9 inhibitors. As expected, high concentration of CDK9 
inhibitors, which will globally blunt elongation preventing any compensatory effect at the 
promoter level, affected the expression of all the tested genes. 
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Fig. 74 JQ1 responsive genes are more sensitive to CDK9i 
Expression analysis by RTqPCR on JQ1 responsive or not-deregulated genes in RAJI in response to two 
different CDK9 inhibitors: in the upper panel, RAJI cells are treated for 3h with different concentration of 
DRB (Mountbatten pink: DMSO, indaco: 0.1 µM, blu persia: 1 µM, lavender: 10 µM, periwinkle: 100 µM), 
in the lower panel RAJI are treated for 24h with different concentration of PHA (Mountbatten pink: DMSO, 
indaco: 0.1 µM, blu persia: 1 µM, lavender: 10 µM). The expression values are normalized on RPP0 
expression and on the DMSO sample. The mean and the standard deviations of 3 technical replicates are 
reported. 
 
Taking advantage of already published data, we analyzed also the RNA PolII dynamics on MM.1S 
cells treated with CDK9 inhibitor  (Anders et al., 2014) using the  (Delmore et al., 2011) 
expression data to define the classes of JQ1 sensitive or insensitive genes. As shown in Fig.75, 
CDK9 inhibitors had a stronger effect respect to BRD4 inhibition in terms of stalling of RNA 
PolII, indeed we observed a decrease in the elongating RNA PolII also in genes classified as not 
responding to BRD4 inhibition. Nonetheless, JQ1 targets showed a greater stalling index with a 
higher reduction in the travelling RNA PolII on the genebody compared to the others, consistent 
with the hypothesis that these genes are intrinsically less capable to compensate for drops in 
elongation rates. 
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Fig. 75 JQ1 responding genes are also more sensitive to CDK9 inhibition 
Evaluation of the RNA PolII dynamics in MM.1S after treatment with DMSO (black) or CDK9 inhibitor 
(red) on genes identified as not-deregulated (NO-DEG), downregulated (DEG-DOWN) or upregulated 
(DEG-UP) after BETs inhibition. (A) Stalling Index is calculated for NO-DEG, DEG-DOWN or DEG-UP 
genes. The left panel summarizes the global SI, the middle panel shows the quantification of RNA PolII on 
the TSS, while the right panel shows the quantification of RNA PolII reads on the GeneBody (GB). (B) 
RNA PolII profiles along the gene for NO-DEG, DEG-DOWN, DEG-UP genes. The dashed line represents 
the background (input) signal. For this analysis already published data are used (Anders et al., 2014; 
Delmore et al., 2011).  
 
The elongation dependency of the genes downregulated by BETs inhibition was further verified in 
CDK9 overexpression experiments. Indeed, ectopic expression of CDK9 (Fig.76) was sufficient to 
slightly increase the expression levels of genes sensitive to JQ1 treatment, while genes insensitive 
to the drug were not altered by CDK9 overexpression (Fig.77).  
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Fig. 76 CDK9 overexpression in RAJI 
Analysis of CDK9 protein level by Western Blot analysis to evaluate CDK9 overexpression in RAJI cells 
infected with either pBabe-PURO-EV or pBabe-PURO-CDK9. Vinculin is used as loading control. One 
technical replicate per each of the two biological replicates was performed and a representative blot is 
shown. 
 
Fig. 77 CDK9 overexpression slightly induces the expression of JQ1 sensitive genes 
Expression analysis by RTqPCR to evaluate the expression levels of genes responsive (downregulated) or 
insensitive (not deregulated) to JQ1 in RAJI infected with either pBabe-Puro-EV (black) or pBabe-Puro-
CDK9 (gray). The expression values are normalized to RPP0 expression levels and pBabe-Puro-EV sample. 
The mean and the standard deviations of 3 technical replicates are reported.  
 
These data suggested that the limiting step in the control of BRD4 targets expression is the 
elongation of RNA PolII. Once this process is perturbed the genes cannot compensate it and their 
transcription will be decreased. On the contrary, the regulation of JQ1 insensitive genes could be 
multilayer allowing to buffer eventual mild perturbation, only heavy alteration of the elongation 
step, as in the case of high concentration of CDK9 inhibitors, will end up with a decrease in their 
expression level. 
 
Super-Enhancers 
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Recent publications have highlighted the presence of new distal regulatory elements, called Super-
enhancers (SEs), characterized by their unusual length and by high levels of BRD4, Med1 and 
H3K27 acetylation  (Lovén et al., 2013). These SE regions are associated to genes that confers cell 
identity or that are necessary for tumor maintenance  (Chapuy et al., 2013; Dowen et al., 2014; 
Hnisz et al., 2013; Lovén et al., 2013; Whyte et al., 2013). The presence and the characteristics of 
those regions were used to support and rationalize the specific downregulation caused by BETs 
inhibitors of some genes associated to tumor progression as c-myc  (Lovén et al., 2013). In order to 
verify if also in RAJI we could identify these regions, we analyzed our BRD4 ChIPseq data 
according to the parameter used in the paper mentioned above (Fig.78).  
 
Fig. 78 Super-enhancers identification in RAJI 
Identification of super-enhancers ranking BRD4 stitched peaks according to BRD4 intensity signal (rpm: 
reads per million). Each ChIPseq sample was sequenced once. 
 
This analysis allowed us to identify in RAJI around 270 Super-enhancers that share features of the 
canonical active enhancers, such as high ratio H3K4me1/H3K4me3 and H3K27Ac (Fig.79).  
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Fig. 79 SEs shows characteristics of distal regulatory regions and they are highly acetylated 
Analysis of histone modifications signal in Super-enhancers (SE), promoters or enhancers. 
H3K4me1/H3K4me3 ratio is used to identify active enhancers, while H3K27Ac is a mark of active and open 
chromatin on SE, promoters or canonical enhancers. The local read density (reads per million/ base pair: 
rpm/bp) is reported. Each ChIPseq sample was sequenced once. 
 
Compared to canonical enhancers, Super-enhancers were particularly enriched for BRD4 binding 
and acetylation on the H3K27 (Fig.80).  
 
Fig. 80 SEs are strongly bound by BRD4 
Analysis of BRD4 intensity binding on Super-enhancers (SE), canonical enhancers or promoters. The local 
read density (reads per million/ base pair: rmp/bp) is reported. 
 
Moreover, SEs were highly sensitive to BETs inhibition, since the treatment with JQ1 caused a 
much stronger BRD4 depletion on SE compared to canonical enhancers (Fig.81). 
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Fig. 81 SEs are highly sensitive to BRD4 displacement mediated by JQ1 
Analysis of BRD4 intensity binding on Super-enhancers (SE) or canonical enhancers (normal) after 24h of 
treatment with DMSO (gray) or 100 nM of JQ1 (red) in RAJI. 
 
Super-enhancers were occupied by Myc and RNA PolII and also in this case, as for canonical 
enhancers and promoters, BETs inhibition caused a local increase of Myc and RNA PolII binding 
(Fig.82). 
 
Fig. 82 SEs are bound by Myc and RNA PolII in RAJI 
Analysis of Myc or RNA PolII intensity binding on Super-enhancers (SE) or canonical enhancers (normal) 
after 24h of treatment with DMSO (gray) or 100 nM of JQ1 (red) in RAJI. Each ChIPseq sample was 
sequenced once. 
 
Since Super-enhancers have been proposed to regulate either cell type specific genes or key 
oncogenes in tumor cell lines and they are particularly sensitive to the treatment with JQ1, we 
wondered whether they were also associated to genes that were downregulated after BETs 
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inhibition in RAJI. To answer to this question, we first associated the Super-enhancers to the 
closest gene and we performed the overlap between the associated Super-enhancers genes and the 
DEGs identified after microarray analysis. None of the classes that we defined as DEGs were 
enriched for genes associated to Super-enhancers (Fig.83).  
 
Fig. 83 SEs associated genes are not enriched for JQ1 responsive genes 
Comparison of Super-Enhancer (SE) associated genes and genes deregulated (DOWN or UP) by JQ1 
treatment in RAJI. The comparison of canonical enhancer associated genes and JQ1 responsive genes is used 
as control. 
 
While we did not find any direct association between genes differentially expressed upon BETs 
inhibition and SE, based on proximity analysis, long-range transcriptional control exerted by SE 
will merit further assessment.  
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V. Discussion 
 
The c-myc gene encodes for a transcription factor involved in different aspects of cellular 
life and, in particular, in cell cycle control and apoptosis, cell differentiation, cell 
metabolism, energy production and RNA synthesis  (Ponzielli et al., 2005). The crucial 
role of Myc in the regulation of cell cycle and cell proliferation was demonstrated shortly 
after its discovery as a viral oncogene in avian leukemia  (Sheiness and Bishop, 1979). 
Hitherto, Myc oncogenic activity has been associated not only to the onset of the vast 
number of human tumors  (Dang, 2012), but also to tumor maintenance  (Pelengaris et al., 
2002b; Shachaf et al., 2004; Soucek et al., 2008). Thus, the development of inhibitory 
strategies aimed at modulating or switching off Myc expression represents “the promise 
land” in cancer treatment. Different strategies have been proposed to impair Myc 
expression or activity  (Ponzielli et al., 2005), among these, in the last years the possibility 
to target chromatin readers has been explored. Indeed, different reports in 2011 
demonstrated that the use of BETs inhibitors led to cell cycle arrest in vitro and tumor 
regression in vivo  (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011; Zuber et 
al., 2011). Moreover, in these publications, Myc downregulation was proposed as the main 
target of BETs inhibitors  (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011; 
Zuber et al., 2011). 
BET proteins are crucial mediators in gene transcription, since, after the recognition and 
the binding of acetylated histones through the bromodomains, they recruit activators of 
transcription, as pTEFb (Jang et al., 2005; Yang et al., 2005).  
Different working models have been proposed to explain how BETs inhibition triggers 
Myc downregulation. Indeed when the c-myc gene is translocated under the control of the 
IgH enhancer, its transcription is regulated by broad regulatory distal regions located in 
the IgH locus, called IgH-Super Enhancers (SE), that are highly enriched for BRD4. In 
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this context, Myc downregulation could be explained by the displacement of BRD4 from 
the IgH-SE  (Delmore et al., 2011; Lovén et al., 2013). When c-myc is not translocated, its 
expression can be regulated by oncogenic transcription factors, as MLL/AF9 in the Acute 
Myeloid Leukemia, recruited on chromatin by BET proteins. Also in this system the 
treatment with BETs inhibitors prevents BET proteins binding to chromatin and switch off 
Myc transcription  (Dawson et al., 2011).  
Subsequent publications, as well as our work, called into question the idea that Myc 
downregulation is a conditio sine qua non BETs inhibitors can exert their therapeutic 
functions. Indeed, we were able to identify different Burkitt’s lymphoma cell lines and 
Eµ-Myc lymphomas that do not show any alteration of Myc levels (Fig.22-23), even if 
highly sensitive to drug treatment in terms of decrease in cell growth (Fig.17) and block in 
G1/S progression (Fig.18). Moreover, our results suggest that, despite the final effect on 
Myc expression, BETs inhibition leads to a deregulation of a restricted class of genes, 
enriched for targets of Myc (Fig.44) and E2F (Fig.45) and involved in cell cycle 
progression (Fig.43). It is worth to highlight that similar classes of genes are 
downregulated in response to BETs inhibitors in different hematological tumors (Burkitt’s 
Lymphomas and Multiple Myeloma), independently from the alteration of Myc levels 
(Fig.47). Indeed, both RAJI (Myc no change) and MM.1S (Myc downregulated) showed a 
strong downregulation of genes involved in the cell cycle progression in response to BETs 
inhibitors. This similarity in the global transcriptional changes in BL and MM, regardless 
the effect on Myc transcription, further reinforces the idea that, beside the already 
proposed Myc-dependent mechanisms, a more general mechanism should exist. 
Despite the growing literature on BET proteins and the use of BETs inhibitors in different 
cellular models, a clear characterization of genes sensitive to BETs inhibition is still 
missing. In our work, we identify an association that may lead to a priori prediction of 
JQ1 responsive genes. Indeed, our results suggest that downregulated genes in RAJI are 
characterized by a high expression level, compared to the not deregulated ones (Fig.59). 
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Moreover, JQ1 responsive genes, not only are enriched for Myc and E2F1 targets, as 
demonstrated by GSEA (Fig.44-45) and ChIPseq (Fig.60-61-62), but also they show the 
strongest intensity binding of those TFs (Myc and E2F1) and RNA PolII on the TSS 
(Fig.64), suggesting an high transcriptional activity.  
Beside the deep characterization of JQ1 responsive genes, our work demonstrates that in 
hematological malignancies (BL, MM, DLBCL) BETs inhibition alters the dynamics of 
RNA PolII both in JQ1 sensitive and insensitive genes. Previous publications already 
showed the involvement of BRD4 in the regulation of RNA PolII rate in different cellular 
systems  (Di Micco et al., 2014; Anand et al., 2013; Kanno et al., 2014; Liu et al., 2014, 
2013). Indeed, it was demonstrated that BRD4 inhibition or silencing are associated to an 
impairment of RNA PolII rate not only in JQ1 responsive genes, but also in the remaining 
active transcripts  (Anand et al., 2013; Liu et al., 2013; Di Micco et al., 2014). While some 
reports associate the regulation of RNA PolII rate mediated by BRD4 to its capacity to 
recruit and activate pTEFb  (Liu et al., 2014), in Ozato’s lab this possibility was excluded 
and the BRD4 control of the elongation rate was connected to its histone chaperone 
activity  (Kanno et al., 2014). In our work, we mainly focused our attention on the analysis 
of the transcriptional consequences to BETs inhibition rather than on the mechanistic 
dissection of BRD4 involvement in the control of the elongation step. Indeed, our results 
add an additional layer of information, thanks to a deeper analysis of RNA PolII 
dynamics: our work, in line with already published reports, demonstrates an increase in the 
Stalling Index (SI) in all active genes as well as in JQ1 sensitive ones (Fig.67-69-70). 
Furthermore we demonstrate that, while not sensitive genes are characterized by an 
increase in the promoter-proximal RNA PolII with no changes on the elongating RNA 
PolII on the genebody, JQ1 responsive genes show a strong decrease in the RNA PolII 
associated to genebody (Fig.67-69-70). It is worth to remember at this point that the SI 
takes into account the amount of RNA PolII both on the TSS and on the genebody, 
consequently an increase in the SI value could be associated to either an increase in the 
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TSS associated RNA PolII or to a decrease in the elongating polymerase. Our work 
suggests that BETs inhibition causes a genome wide alteration of RNA PolII dynamics 
with an increase in the SI value: while JQ1 sensitive genes experience a drop in the 
elongating RNA PolII, JQ1 insensitive genes actively recruit more RNA PolII on the TSS. 
Furthermore, our results suggest that the active recruitment of total RNA PolII on the TSS 
of JQ1 insensitive genes is followed by an active phosphorylation on the polymerase CTD, 
since we observed an increase of both S5p TSS associated (Fig.73) and S2p elongating 
RNA PolII (Fig.72). On the contrary, JQ1 sensitive genes were characterized by the 
absence of additional phosphorylation after BETs inhibition, since the amount of RNA 
PolII phosphorylated forms over the total was comparable among DMSO and JQ1 sample 
(Fig.72-73).  
Overall, the analysis of RNA PolII clearly demonstrated that two different responses are 
possible after BETs inhibition: while JQ1 insensitive genes recruit more RNA PolII on the 
promoter and respond to BETs inhibition increasing the phosphorylation of the 
polymerase, JQ1 sensitive genes show a strong reduction in the elongating RNA PolII 
without any further recruitment or phosphorylation of new RNA PolII molecules.  
Comprehensively, our work proposes a novel mechanism of action for BETs inhibitors. 
Indeed our data show that, beside the already proposed direct downregulation of key 
Transcription Factors as Myc, another JQ1 effect is the alteration of RNA PolII dynamics: 
while JQ1 responsive genes transcription is strongly reduced after drug treatment due to a 
drop in the elongating RNA PolII, JQ1 not responsive genes are able to compensate the 
alteration of the polymerase distribution increasing both the total amount of TFs and RNA 
PolII on the promoter and the phosphorylation of polymerase in order to enhance its 
processivity. Probably this compensatory mechanism is not possible in the class of JQ1 
sensitive genes because they are already expressed at their maximum level. Furthermore, 
our work suggests that for highly transcribed genes the elongation step is a rate limiting 
step, since they are highly sensitive to any alteration of RNA PolII elongating fraction and 
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they are not able to compensate this change. In this light, our work not only suggests a 
novel BETs inhibitor mechanism of action but highlights the possibility to use the 
elongation step as an additional potential therapeutic target. 
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